



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C07D 403/06, A61K 31/495 // (C07D 403/06, 231:00, 295:00)	A1	(11) International Publication Number: WO 94/21630 (43) International Publication Date: 29 September 1994 (29.09.94)
(21) International Application Number: PCT/GB94/00504 (22) International Filing Date: 14 March 1994 (14.03.94) (30) Priority Data: 9305623.2 18 March 1993 (18.03.93) GB (71) Applicant (for all designated States except US): MERCK SHARP & DOHME LIMITED [GB/GB]; Hertford Road, Hoddesdon, Hertfordshire EN11 9BU (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): BAKER, Raymond [GB/GB]; Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR (GB). KULAGOWSKI, Janusz, Jozef [GB/GB]; Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR (GB). LEESON, Paul, David [GB/GB]; Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR (GB). SMITH, Adrian, Leonard [GB/GB]; Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR (GB). (74) Agent: THOMPSON, John; Merck & Co., Inc., Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR (GB).		(81) Designated States: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, LV, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: ANTIPSYCHOTIC INDAZOLE DERIVATIVES		
(57) Abstract <p>A class of 1H-indazole derivatives, substituted at the 3-position by a substituted piperazinylmethyl moiety, are antagonists of dopamine receptor subtypes within the brain, having a selective affinity for the dopamine D₄ receptor subtype over other dopamine receptor subtypes, and are accordingly of benefit in the treatment and/or prevention of psychotic disorders such as schizophrenia whilst manifesting fewer side-effects than those associated with classical neuroleptic drugs.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

- 1 -

ANTIPSYCHOTIC INDAZOLE DERIVATIVES

This invention relates to the use of a particular class of heteroaromatic compounds. More particularly, the invention is concerned with the use of substituted indazole derivatives which are antagonists of dopamine receptor subtypes within the brain and are therefore of benefit in the treatment and/or prevention of psychotic disorders such as schizophrenia.

The "dopamine hypothesis" of schizophrenia predicts an increased activity of dopamine neurotransmission in the disease. The hypothesis is supported by early observations that drugs, such as amphetamine, with dopamine agonist or dopamine-releasing properties are capable of eliciting a psychosis indistinguishable from acute paranoid schizophrenia.

Schizophrenia is a disorder which is conventionally treated with drugs known as neuroleptics. In the majority of cases, the symptoms of schizophrenia can be treated successfully with so-called "classical" neuroleptic agents such as haloperidol. Classical neuroleptics generally are antagonists at dopamine D₂ receptors. The fact that classical neuroleptic drugs have an action on dopamine receptors in the brain thus lends credence to the "dopamine hypothesis" of schizophrenia.

Molecular biological techniques have revealed the existence of several subtypes of the dopamine receptor. The dopamine D₁ receptor subtype has been shown to occur in at least two discrete forms. Two forms of the D₂ receptor subtype, and at least one form of the D₃ receptor subtype, have also been discovered. More recently, the D₄ (Van Tol *et al.*, *Nature* (London), 1991, 350, 610) and D₅ (Sunahara *et al.*, *Nature* (London), 1991, 350, 614) receptor subtypes have been described.

- 2 -

Notwithstanding their beneficial antipsychotic effects, classical neuroleptic agents such as haloperidol are frequently responsible for eliciting acute extrapyramidal symptoms and neuroendocrine disturbances.

5 These side-effects, which clearly detract from the clinical desirability of classical neuroleptics, are believed to be attributable to D₂ receptor blockade in the striatal region of the brain. It is considered (Van Tol et al., supra) that compounds which can interact

10 selectively with the dopamine D₄ receptor subtype, whilst having a less-pronounced action at the D₂ subtype, might be free from, or at any rate less prone to, the side-effects associated with classical neuroleptics, whilst at the same time maintaining a beneficial level of

15 antipsychotic activity.

The compounds of use in the present invention, being antagonists of dopamine receptor subtypes within the brain, are accordingly of benefit in the treatment and/or prevention of psychotic disorders such as

20 schizophrenia. Moreover, the compounds of use in the invention have a selective affinity for the dopamine D₄ receptor subtype over other dopamine receptor subtypes, in particular the D₂ subtype, and can therefore be expected to manifest fewer side-effects than those

25 associated with classical neuroleptic drugs.

US Patent 3362956 describes certain 1-[(heterocyclyl)-lower-alkyl]-4-substituted-piperazines, in which the heterocyclyl moiety represents inter alia an indazole group (also referred to therein as a 2-azaindole group).

30 These compounds are alleged therein to possess a panoply of depressant actions on the autonomic nervous system, the cardiovascular system and the skeletal muscular system (including psychomotor depressant, sedative, adrenolytic, rectal temperature lowering,

35 anticonvulsant, blood pressure lowering and heart force increasing activities), and are consequently alleged to

- 3 -


be useful as tranquilizers, sedatives, adrenolytic agents, hypothermic agents, anti-convulsants, hypotensive agents and cardiovascular agents.

5 A related series of compounds, which are stated to be cholinesterase inhibitors and thus useful in enhancing memory in patients suffering from dementia and Alzheimer's disease, is described in WO-A-92/17475.

10 The disclosure of US Patent 3678059 generically encompasses inter alia a class of 3-[piperazin-1-ylalkyl]indazole derivatives substituted on the indazole nitrogen atom by an araliphatic or aromatic radical. These compounds are alleged therein to possess antidepressant and anti-inflammatory activity.

15 There is, however, no suggestion in US Patents 3362956 or 3678059, or in WO-A-92/17475, that the compounds described therein would be of any benefit in the treatment and/or prevention of psychotic disorders such as schizophrenia, still less that in doing so they might be expected to manifest fewer side-effects than
20 those exhibited by classical neuroleptic agents.

The present invention accordingly provides the use of a compound of formula I, or a pharmaceutically acceptable salt thereof or a prodrug thereof:



(I)

wherein

35

R represents hydrogen or C₁₋₆ alkyl;

- 4 -

R^1 represents hydrogen, or an optionally substituted C_{1-6} alkyl, C_{1-6} alkoxy, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-7} cycloalkyl, C_{3-7} cycloalkyl(C_{1-6})alkyl, aryl, aryl(C_{1-6})alkyl, aryl(C_{1-6})alkoxy, aryl(C_{2-6})alkenyl, aryl(C_{2-6})alkynyl, heteroaryl, heteroaryl(C_{1-6})alkyl, heteroaryl(C_{2-6})alkenyl or heteroaryl(C_{2-6})alkynyl group;

R^2 represents an optionally substituted C_{1-6} alkyl, C_{1-6} alkoxy, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-7} cycloalkyl, C_{3-7} cycloalkyl(C_{1-6})alkyl, aryl, aryl(C_{1-6})alkyl, aryl(C_{1-6})alkoxy, aryl(C_{2-6})alkenyl, aryl(C_{2-6})alkynyl, heteroaryl, heteroaryl(C_{1-6})alkyl, heteroaryl(C_{2-6})alkenyl or heteroaryl(C_{2-6})alkynyl group;

R^3 , R^4 and R^5 independently represent hydrogen, hydrocarbon, a heterocyclic group, halogen, cyano, trifluoromethyl, nitro, $-OR^a$, $-SR^a$, $-SOR^a$, $-SO_2R^a$, $-SO_2NR^aR^b$, $-NR^aR^b$, $-NR^aCOR^b$, $-NR^aCO_2R^b$, $-COR^a$, $-CO_2R^a$ or $-CONR^aR^b$; and

R^a and R^b independently represent hydrogen, hydrocarbon or a heterocyclic group; for the manufacture of a medicament for the treatment and/or prevention of psychotic disorders such as schizophrenia.

For use in medicine, the salts of the compounds of formula I will be pharmaceutically acceptable salts. Other salts may, however, be useful in the preparation of the compounds of use in the invention or of their pharmaceutically acceptable salts. Suitable pharmaceutically acceptable salts of the compounds of use in this invention include acid addition salts which may, for example, be formed by mixing a solution of the compound of use in the invention with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, sulphuric acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, oxalic acid, citric acid, tartaric acid, carbonic acid or phosphoric acid.

- 5 -

Furthermore, where the compounds of use in the invention carry an acidic moiety, suitable pharmaceutically acceptable salts thereof may include alkali metal salts, e.g. sodium or potassium salts; alkaline earth metal salts, e.g. calcium or magnesium salts; and salts formed with suitable organic ligands, e.g. quaternary ammonium salts.

The term "hydrocarbon" as used herein includes straight-chained, branched and cyclic groups containing up to 18 carbon atoms, suitably up to 15 carbon atoms, and conveniently up to 12 carbon atoms. Suitable hydrocarbon groups include C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkyl(C₁₋₆)alkyl, aryl, aryl(C₁₋₆)alkyl, aryl(C₂₋₆)alkenyl and aryl(C₂₋₆)alkynyl.

The expression "a heterocyclic group" as used herein includes cyclic groups containing up to 18 carbon atoms and at least one heteroatom preferably selected from oxygen, nitrogen and sulphur. The heterocyclic group suitably contains up to 15 carbon atoms and conveniently up to 12 carbon atoms, and is preferably linked through carbon. Examples of suitable heterocyclic groups include C₃₋₇ heterocycloalkyl, C₃₋₇ heterocycloalkyl(C₁₋₆)alkyl, heteroaryl, heteroaryl(C₁₋₆)alkyl, heteroaryl(C₂₋₆)alkenyl and heteroaryl(C₂₋₆)alkynyl groups.

Suitable alkyl groups within the scope of the term "hydrocarbon" and within the definition of the substituents R, R¹ and R² include straight-chained and branched alkyl groups containing from 1 to 6 carbon atoms. Typical examples include methyl and ethyl groups, and straight-chained or branched propyl and butyl groups. Particular alkyl groups are methyl, ethyl, n-propyl, isopropyl and t-butyl.

Suitable alkenyl groups within the scope of the term "hydrocarbon" and within the definition of the

- 6 -

substituents R^1 and R^2 include straight-chained and branched alkenyl groups containing from 2 to 6 carbon atoms. Typical examples include vinyl and allyl groups.

5 Suitable alkynyl groups within the scope of the term "hydrocarbon" and within the definition of the substituents R^1 and R^2 include straight-chained and branched alkynyl groups containing from 2 to 6 carbon atoms. Typical examples include ethynyl and propargyl groups.

10 Suitable cycloalkyl groups within the scope of the term "hydrocarbon" and within the definition of the substituents R^1 and R^2 include groups containing from 3 to 7 carbon atoms. Particular cycloalkyl groups are cyclopropyl and cyclohexyl.

15 Particular cycloalkyl(C_{1-6})alkyl groups within the scope of the term "hydrocarbon" and within the definition of the substituents R^1 and R^2 include cyclopropylmethyl, cyclohexylmethyl and cyclohexylethyl.

20 Particular aryl groups within the scope of the term "hydrocarbon" and within the definition of the substituents R^1 and R^2 include phenyl and naphthyl.

25 Particular aryl(C_{1-6})alkyl groups within the scope of the term "hydrocarbon" and within the definition of the substituents R^1 and R^2 include benzyl, naphthylmethyl, phenethyl and phenylpropyl.

 Suitable heterocycloalkyl groups include azetidiny, pyrrolidyl, piperidyl, piperazinyl and morpholinyl groups.

30 Suitable heteroaryl groups within the scope of the expression "a heterocyclic group" and within the definition of the substituents R^1 and R^2 include pyridyl, quinolyl, isoquinolyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyranyl, furyl, benzofuryl, dibenzofuryl, thienyl, benzthienyl, imidazolyl, oxadiazolyl and
35 thiadiazolyl groups.

- 7 -

Particular heteroaryl(C₁₋₆)alkyl groups within the scope of the expression "a heterocyclic group" and within the definition of the substituents R¹ and R² include thienylmethyl, pyridylmethyl, pyrimidinylmethyl and pyrazinylmethyl.

The hydrocarbon and heterocyclic groups, as well as the substituents R¹ and R², may in turn be optionally substituted by one or more groups selected from C₁₋₆ alkyl, adamantyl, phenyl, aryl(C₁₋₆)alkyl, halogen, C₁₋₆ haloalkyl, C₁₋₆ aminoalkyl, trifluoromethyl, hydroxy, C₁₋₆ alkoxy, aryloxy, keto, C₁₋₃ alkylenedioxy, nitro, cyano, carboxy, C₂₋₆ alkoxy carbonyl, C₂₋₆ alkoxy carbonyl(C₁₋₆)alkyl, C₂₋₆ alkyl carbonyloxy, aryl carbonyloxy, C₂₋₆ alkyl carbonyl, aryl carbonyl, C₁₋₆ alkylthio, C₁₋₆ alkylsulphinyl, C₁₋₆ alkylsulphonyl, arylsulphonyl, -NR^VR^W, -NR^VCOR^W, -NR^VCO₂R^W, -NR^VSO₂R^W, -CH₂NR^VSO₂R^W, -NHCONR^VR^W, -CONR^VR^W, -SO₂NR^VR^W and -CH₂SO₂NR^VR^W, in which R^V and R^W independently represent hydrogen, C₁₋₆ alkyl, aryl or aryl(C₁₋₆)alkyl.

The term "halogen" as used herein includes fluorine, chlorine, bromine and iodine, especially chlorine.

The present invention includes within its scope the use of prodrugs of the compounds of formula I above. In general, such prodrugs will be functional derivatives of the compounds of formula I which are readily convertible in vivo into the required compound of formula I. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in "Design of Prodrugs", ed. H. Bundgaard, Elsevier, 1985.

Where the compounds of use in the invention have at least one asymmetric centre, they may accordingly exist as enantiomers. Where the compounds of use in the invention possess two or more asymmetric centres, they

- 8 -

may additionally exist as diastereoisomers. It is to be understood that the use of all such isomers and mixtures thereof is encompassed within the scope of the present invention.

5 Suitably, the substituent R represents hydrogen or methyl, especially hydrogen.

 Suitably, the substituent R¹ represents hydrogen or methyl, especially hydrogen.


 Suitable values for the substituent R² include
10 C₁₋₆ alkyl, C₃₋₇ cycloalkyl(C₁₋₆)alkyl, aryl,
 aryl(C₁₋₆)alkyl and heteroaryl, any of which groups may
 be optionally substituted. Examples of optional
 substituents on the group R² include C₁₋₆ alkyl, halogen,
 trifluoromethyl, C₁₋₆ alkoxy, keto, C₁₋₃ alkylenedioxy,
15 nitro and C₂₋₆ alkylcarbonyl.

 Particular values of R² include methyl, ethyl,
 n-propyl, isopropyl, cyclohexyl-ethyl, phenyl,
 methylphenyl, ethylphenyl, fluorophenyl, chlorophenyl,
 trifluoromethyl-phenyl, bis(trifluoromethyl)-phenyl,
20 methoxyphenyl, methylenedioxy-phenyl, acetylphenyl,
 nitrophenyl, benzyl, chlorobenzyl, methylenedioxy-benzyl,
 benzylcarbonyl, phenethyl, pyridyl, chloropyridyl,
 methylpyridyl, trifluoromethyl-pyridyl, methoxypyridyl,
 quinolyl, isoquinolyl and pyrimidinyl.

25 Suitable values for the substituents R³, R⁴ and
 R⁵ include hydrogen, halogen, cyano, nitro,
 trifluoromethyl, amino, C₁₋₆ alkylamino,
 di(C₁₋₆)alkylamino, C₁₋₆ alkyl, C₁₋₆ alkoxy,
 aryl(C₁₋₆)alkoxy and C₂₋₆ alkylcarbonyl. Particular
30 values include hydrogen, fluoro, chloro, iodo, methyl,
 methoxy and benzyloxy.

 A particular sub-class of compounds of use in
 the invention is represented by the compounds of formula
 IIA, and pharmaceutically acceptable salts thereof and
35 prodrugs thereof:

- 9 -



(IIA)

wherein

n is zero, 1, 2 or 3;

R^{11} represents hydrogen or C_{1-6} alkyl;

R^{13} and R^{14} independently represent hydrogen,
 15 halogen, cyano, nitro, trifluoromethyl, amino, C_{1-6}
 alkylamino, di(C_{1-6})alkylamino, C_{1-6} alkyl, C_{1-6} alkoxy,
 aryl(C_{1-6})alkoxy or C_{2-6} alkylcarbonyl; or R^{13} and R^{14} ,
 when situated on adjacent carbon atoms, together
 represent methylenedioxy; and

20 R^{17} and R^{18} independently represent hydrogen,
 halogen, cyano, nitro, trifluoromethyl, amino, C_{1-6}
 alkylamino, di(C_{1-6})alkylamino, C_{1-6} alkyl, C_{1-6} alkoxy,
 aryl(C_{1-6})alkoxy or C_{2-6} alkylcarbonyl; or R^{17} and R^{18} ,
 when situated on adjacent carbon atoms, together
 25 represent methylenedioxy.

Particular values of R^{11} include hydrogen and
 methyl, especially hydrogen.


Particular values of R^{13} and R^{14} include
 hydrogen, halogen, methyl, ethyl, methoxy and benzyloxy,
 30 especially hydrogen, fluoro, chloro and iodo. Suitably,
 one of R^{13} and/or R^{14} is hydrogen.

Particular values of R^{17} and R^{18} include
 hydrogen, fluoro, chloro, trifluoromethyl, methyl,
 methoxy, acetyl and nitro. Suitably, one of R^{17} and/or
 35 R^{18} is hydrogen.

- 10 -

In a subset of the compounds of formula IIA above, R^{14} and R^{18} both represent hydrogen.

Another sub-class of compounds of use in the invention is represented by the compounds of formula IIB,
 5 and pharmaceutically acceptable salts thereof and prodrugs thereof:




(IIB)


wherein

n , R^{11} , R^{13} and R^{14} are as defined with reference to formula IIA above; and


20 Yd: Y represents a group of formula Ya, Yb, Yc or Yd:




(Ya)



(Yb)



(Yc)



(Yd)

- 11 -

in which

R^{27} represents halogen, trifluoromethyl, C_{1-6} alkyl or C_{1-6} alkoxy; and

R^{28} represents hydrogen, halogen,
5 trifluoromethyl, C_{1-6} alkyl or C_{1-6} alkoxy.

Particular values of R^{27} include chloro, trifluoromethyl, methyl and methoxy.

Particular values of R^{28} include hydrogen, chloro, trifluoromethyl, methyl and methoxy, especially
10 hydrogen.

In a subset of the compounds of formula IIB above, R^{14} represents hydrogen, Y represents a group of formula Ya, Yb or Yc, and R^{27} and R^{28} are other than trifluoromethyl.

15 Certain compounds falling within the scope of formula I above are novel. A particular sub-class of novel compounds in accordance with the present invention comprises the compounds of formula IIB as defined above, and salts and prodrugs thereof. The invention further
20 provides a novel compound selected from the following:

3-[4-(4-chlorophenyl)piperazin-1-ylmethyl]-1H-indazole;
3-(4-phenylpiperazin-1-ylmethyl)-1H-indazole;
3-(4-benzylpiperazin-1-ylmethyl)-1H-indazole;
3-(3-methyl-4-phenylpiperazin-1-ylmethyl)-1H-indazole;
25 3-[4-(4-fluorophenyl)piperazin-1-ylmethyl]-1H-indazole;
3-[4-(2-methylphenyl)piperazin-1-ylmethyl]-1H-indazole;
3-[4-(3-methylphenyl)piperazin-1-ylmethyl]-1H-indazole;
3-[4-(4-methylphenyl)piperazin-1-ylmethyl]-1H-indazole;
3-[4-(pyrimidin-2-yl)piperazin-1-ylmethyl]-1H-indazole;
30 3-[4-(3,4-methylenedioxybenzyl)piperazin-1-ylmethyl]-1H-indazole;
3-[4-(3-trifluoromethylphenyl)piperazin-1-ylmethyl]-1H-indazole;
3-[4-(pyrid-2-yl)piperazin-1-ylmethyl]-1H-indazole;
35 3-[4-(4-methoxyphenyl)piperazin-1-ylmethyl]-1H-indazole;
3-[4-(4-acetylphenyl)piperazin-1-ylmethyl]-1H-indazole;

- 12 -

- 6-fluoro-3-[4-(4-methoxyphenyl)piperazin-1-ylmethyl]-1H-indazole;
3-[4-(4-chlorophenyl)piperazin-1-ylmethyl]-6-fluoro-1H-indazole;
5 6-fluoro-3-[4-(2-phenylethyl)piperazin-1-ylmethyl]-1H-indazole;
6-chloro-3-[4-(4-methoxyphenyl)piperazin-1-ylmethyl]-1H-indazole;
7-chloro-3-[4-(4-methoxyphenyl)piperazin-1-ylmethyl]-1H-indazole;
10 3-[4-(2-phenylethyl)piperazin-1-ylmethyl]-1H-indazole;
3-[4-(5-chloropyrid-2-yl)piperazin-1-ylmethyl]-1H-indazole;
3-[4-(5-methylpyrid-2-yl)piperazin-1-ylmethyl]-1H-indazole;
15 3-[4-(5-methoxypyrid-2-yl)piperazin-1-ylmethyl]-1H-indazole;
3-[4-(quinolin-2-yl)piperazin-1-ylmethyl]-1H-indazole;
3-[4-(isoquinolin-3-yl)piperazin-1-ylmethyl]-1H-indazole;
20 3-[4-(3,4-methylenedioxyphenyl)piperazin-1-ylmethyl]-1H-indazole;
3-[4-(3,5-bis(trifluoromethyl)phenyl)piperazin-1-ylmethyl]-1H-indazole;
3-[4-(5-trifluoromethylpyrid-2-yl)piperazin-1-ylmethyl]-1H-indazole;
25 3-[4-(4-trifluoromethylpyrid-2-yl)piperazin-1-ylmethyl]-1H-indazole;
3-(4-benzylcarbonylpiperazin-1-ylmethyl)-6-fluoro-1H-indazole;
30 7-iodo-3-[4-(4-methoxyphenyl)piperazin-1-ylmethyl]-1H-indazole;
7-fluoro-3-[4-(4-methoxyphenyl)piperazin-1-ylmethyl]-1H-indazole;
7-fluoro-3-[4-(4-methylphenyl)piperazin-1-ylmethyl]-1H-indazole;
35

- 13 -

- 6,7-difluoro-3-[4-(4-methoxyphenyl)piperazin-1-ylmethyl]-
1H-indazole;
3-[4-(4-chlorophenyl)piperazin-1-ylmethyl]-6,7-difluoro-
1H-indazole;
5 7-chloro-3-[4-(4-chlorophenyl)piperazin-1-ylmethyl]-1H-
indazole;
7-chloro-3-[4-(3,4-methylenedioxyphenyl)piperazin-1-
ylmethyl]-1H-indazole;
7-chloro-3-[4-(3-trifluoromethylphenyl)piperazin-1-
10 ylmethyl]-1H-indazole;
7-chloro-3-[4-(4-methylphenyl)piperazin-1-ylmethyl]-1H-
indazole;
7-chloro-3-[4-(5-chloropyrid-2-yl)piperazin-1-ylmethyl]-
1H-indazole;
15 7-chloro-3-[4-(isoquinolin-3-yl)piperazin-1-ylmethyl]-1H-
indazole;
and salts and prodrugs thereof.

The invention also provides pharmaceutical
compositions comprising one or more of the novel
20 compounds according to the invention in association with
a pharmaceutically acceptable carrier. Preferably these
compositions are in unit dosage forms such as tablets,
pills, capsules, powders, granules, sterile parenteral
solutions or suspensions, metered aerosol or liquid
25 sprays, drops, ampoules, auto-injector devices or
suppositories; for oral, parenteral, intranasal,
sublingual or rectal administration, or for
administration by inhalation or insufflation.
Alternatively, the compositions may be presented in a
30 form suitable for once-weekly or once-monthly
administration; for example, an insoluble salt of the
active compound, such as the decanoate salt, may be
adapted to provide a depot preparation for intramuscular
injection. For preparing solid compositions such as
35 tablets, the principal active ingredient is mixed with a
pharmaceutical carrier, e.g. conventional tableting

- 14 -

ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate or gums, and other pharmaceutical diluents, e.g. water, to form a solid preformulation composition containing a homogeneous mixture of a compound of the present invention, or a pharmaceutically acceptable salt thereof. When referring to these preformulation compositions as homogeneous, it is meant that the active ingredient is dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules. This solid preformulation composition is then subdivided into unit dosage forms of the type described above containing from 0.1 to about 500 mg of the active ingredient of the present invention. The tablets or pills of the novel composition can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol and cellulose acetate.


The liquid forms in which the novel compositions of the present invention may be incorporated for administration orally or by injection include aqueous solutions, suitably flavoured syrups, aqueous or oil suspensions, and flavoured emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil or peanut

- 15 -


oil, as well as elixirs and similar pharmaceutical vehicles. Suitable dispersing or suspending agents for aqueous suspensions include synthetic and natural gums such as tragacanth, acacia, alginate, dextran, sodium
 5 carboxymethylcellulose, methylcellulose, polyvinylpyrrolidone or gelatin.

In the treatment of schizophrenia, a suitable dosage level is about 0.01 to 250 mg/kg per day, preferably about 0.05 to 100 mg/kg per day, and
 10 especially about 0.05 to 5 mg/kg per day. The compounds may be administered on a regimen of 1 to 4 times per day.

The compounds of formula I above, including the novel compounds according to the present invention, may be prepared by a process which comprises reacting a
 15 compound of formula III with a compound of formula IV:



(III)



(IV)

wherein R^1 , R^2 , R^3 , R^4 and R^5 are as defined above, L represents a suitable leaving group, and R^P corresponds to the group R as defined above or represents a suitable
 30 protecting group; followed, where required, by removal of the protecting group R^P ; and subsequently, if necessary, N-alkylation by standard methods to introduce the moiety R.


The leaving group L is suitably a halogen atom,
 35 e.g. bromine.

- 16 -

The protecting group R^P on the indazole nitrogen atom, when present, is suitably an acyl moiety such as acetyl, which can conveniently be removed as necessary by treatment under strongly basic conditions, e.g. sodium methoxide in methanol. Alternatively, the protecting group R^P may be a carbamoyl moiety such as t-butoxycarbonyl (BOC), which can conveniently be removed as necessary by treatment under mildly acidic conditions.

The reaction between compounds III and IV is conveniently carried out by stirring the reactants under basic conditions in a suitable solvent, for example potassium carbonate in N,N-dimethylformamide; triethylamine in tetrahydrofuran or acetonitrile; or diisopropylethylamine (Hünig's base) in dichloromethane.

In an alternative procedure, the compounds of formula I above, including the novel compounds according to the present invention, may be prepared by a process which comprises reducing a compound of formula V:




(V)

wherein R^1 , R^2 , R^3 , R^4 , R^5 and R^P are as defined above; followed, where required, by removal of the protecting group R^P ; and subsequently, if necessary, N-alkylation by standard methods to introduce the moiety R.

The reaction is conveniently carried out by treating the compound V with a reducing agent such as lithium aluminium hydride in an appropriate solvent, e.g. tetrahydrofuran.

- 17 -

The intermediates of formula V above may suitably be prepared by reacting a compound of formula IV as defined above with a compound of formula VI:



(VI)

wherein R³, R⁴, R⁵ and R^P are as defined above; and W represents a reactive carboxylate moiety.

15 Suitable values for the reactive carboxylate moiety W include esters, for example C₁₋₄ alkyl esters; acid anhydrides, for example mixed anhydrides with C₁₋₄ alkanolic acids; acid halides, for example acid chlorides; and acylimidazoles.

20 By way of example, the intermediates of formula VI above wherein W is an acid chloride moiety may be prepared by treating the corresponding carboxylic acid derivative with thionyl chloride in toluene. Similarly, the intermediates of formula VI wherein W is an

25 acylimidazole moiety may be prepared by treating the corresponding carboxylic acid derivative with 1,1'-carbonyldiimidazole. Alternatively, the reactive carboxylate moiety W may be obtained by treating the corresponding compound wherein W is carboxy with 1-(3-

30 dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride and 1-hydroxybenzotriazole hydrate, optionally in the presence of triethylamine; the resulting activated carboxylate intermediate may then suitably be reacted in situ with the required compound of formula IV.

35 Where they are not commercially available, the starting materials of formula III, IV and VI may be

- 18 -

prepared by procedures analogous to those described in the accompanying Examples, or by standard methods well known from the art.

It will be appreciated that any compound of formula I initially obtained from any of the above processes may, where appropriate, subsequently be elaborated into a further desired compound of formula I using techniques known from the art. For example, a compound of formula I wherein R is hydrogen initially obtained may be converted into a compound of formula I wherein R represents C₁₋₆ alkyl by standard alkylation techniques, such as by treatment with an alkyl iodide, e.g. methyl iodide, typically under basic conditions, e.g. sodium hydride in dimethylformamide, or triethylamine in acetonitrile.

Where the above-described processes for the preparation of the compounds of use in the invention give rise to mixtures of stereoisomers, these isomers may be separated by conventional techniques such as preparative chromatography. The compounds may be prepared in racemic form, or individual enantiomers may be prepared either by enantiospecific synthesis or by resolution. The compounds may, for example, be resolved into their component enantiomers by standard techniques such as preparative HPLC, or the formation of diastereomeric pairs by salt formation with an optically active acid, such as (-)-di-p-toluoyl-d-tartaric acid and/or (+)-di-p-toluoyl-l-tartaric acid, followed by fractional crystallization and regeneration of the free base. The compounds may also be resolved by formation of diastereomeric esters or amides, followed by chromatographic separation and removal of the chiral auxiliary.

During any of the above synthetic sequences it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This

- 19 -

may be achieved by means of conventional protecting groups, such as those described in Protective Groups in Organic Chemistry, ed. J.F.W. McOmie, Plenum Press, 1973; and T.W. Greene & P.G.M. Wuts, Protective Groups in Organic Synthesis, John Wiley & Sons, 1991. The protecting groups may be removed at a convenient subsequent stage using methods known from the art.

The following Examples illustrate the preparation of compounds according to the invention.

The compounds useful in this invention potentially inhibit [^3H]-spiperone binding to human dopamine D_4 receptor subtypes expressed in clonal cell lines.

[^3H]-Spiperone Binding Studies

Clonal cell lines expressing the human dopamine D_4 receptor subtype were harvested in PBS and then lysed in 10 mM Tris-HCl pH 7.4 buffer containing 5 mM MgSO_4 for 20 min on ice. Membranes were centrifuged at 50,000g for 15 min at 4°C and the resulting pellets resuspended in assay buffer (50 mM Tris-HCl pH 7.4 containing 5 mM EDTA, 1.5 mM CaCl_2 , 5 mM MgCl_2 , 5 mM KCl, 120 mM NaCl, and 0.1% ascorbic acid) at 20 mg/ml wet weight. Incubations were carried out for 60 min at room temperature (22°C) in the presence of 0.05-2 nM [^3H]-spiperone or 0.2 nM for displacement studies and were initiated by addition of 20-100 μg protein in a final assay volume of 0.5 ml. The incubation was terminated by rapid filtration over GF/B filters presoaked in 0.3% PEI and washed with 10 ml ice-cold 50 mM Tris-HCl, pH 7.4. Specific binding was determined by 10 μM apomorphine and radioactivity determined by counting in a LKB beta counter. Binding parameters were determined by non-linear least squares regression analysis, from which the inhibition constant K_i could be calculated for each test compound.

- 20 -

The compounds of the accompanying Examples were tested in the above assay, and all were found to possess a K_i value for displacement of [^3H]-spiperone from the human dopamine D_4 receptor subtype of below $1.5 \mu\text{M}$.

EXAMPLES

General techniques: All reactions were carried out under a nitrogen atmosphere using anhydrous solvents under anhydrous conditions unless otherwise noted. Yields refer to chromatographically (HPLC / TLC) and spectroscopically (¹H NMR) homogeneous materials, unless otherwise stated.

All reactions were monitored by thin-layer chromatography carried out on 0.25 mm E. Merck silica gel plates (60F-254) using UV light and/or I₂ vapour for visualisation. Fluka silica gel (60, particle size 0.035 – 0.070 mm) was used for flash chromatography.

EXAMPLE 1

3-[4-(4-Chlorophenyl)piperazin-1-ylmethyl]-1H-indazole

1H-Indazole-3-carboxylic acid (0.774 g, 4.78 mmol), 1-(4-chlorophenyl)piperazine dihydrochloride (2.15 g, 8 mmol), 1-hydroxybenzotriazole hydrate (1.11 g, 8 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (1.57 g, 8 mmol) were suspended in CH₂Cl₂ (50 mL) and treated with *N,N*-diisopropylethylamine (Hünig's base, 2.79 mL, 16 mmol). The mixture was stirred at 20 °C for 14 h during which time the suspension dissolved.

The solution was poured into water (100 mL) and extracted with CH₂Cl₂ (3 x 100 mL). The combined organic extracts were dried (MgSO₄) and concentrated. The residue was dissolved in refluxing EtOAc (50 mL), filtered and concentrated to give a yellow solid (2.215 g).

- 22 -

A suspension of the above solid (2.215 g, 6.50 mmol) in THF (20 mL) was treated with LiAlH₄ (9.75 mL of a 1.0 M solution in THF, 9.75 mmol) and the resulting solution was heated at 40 °C for 14 h. The solution was cooled, quenched by the cautious addition of 2 M aqueous NaOH (1.6 mL), stirred for 1 h at 20 °C, filtered washing with EtOAc, and the filtrate was concentrated and the residue purified by flash chromatography (50% → 75% EtOAc in hexane) to give the title compound as a white solid (910 mg, 58% based upon 1*H*-indazole-3-carboxylic acid). This was recrystallised from EtOAc to give a fluffy white crystalline solid; mp 223 – 224 °C (from EtOAc); ¹H NMR (360 MHz, d₆-DMSO) δ 12.82 (bs, 1 H, NH), 7.87 (d, *J* = 8.1 Hz, 1 H, indazole), 7.48 (d, *J* = 8.4 Hz, 1 H, indazole), 7.33 (dd, *J* = 7.1, 8.1 Hz, 1 H, indazole), 7.20 (d, *J* = 9.1 Hz, 2 H, Ph), 7.09 (dd, *J* = 7.4, 8.4 Hz, 1 H, indazole), 6.91 (d, *J* = 9.1 Hz, 2 H, Ph), 3.88 (s, 2 H, indazole-CH₂-N), 3.11 (bt, *J* = 4.8 Hz, 4 H, piperazine), 2.57 (bt, *J* = 5.0 Hz, 4 H, piperazine); MS (CI+) *m/e* 327/329 (3:1, M+H⁺); Anal. calcd for C₁₈H₁₉N₄Cl: C, 66.15; H, 5.86; N, 17.14. Found: C, 66.48; H, 5.87; N, 16.92.

20

EXAMPLE 23-[4-Phenylpiperazin-1-ylmethyl]-1*H*-indazole

The title compound was prepared as a fluffy white crystalline solid following the general procedure described in EXAMPLE 1; mp 196 – 197 °C (from Et₂O); ¹H NMR (360 MHz, d₆-DMSO) δ 7.88 (d, *J* = 8.1 Hz, 1 H, indazole), 7.49 (d, *J* = 8.4 Hz, 1 H, indazole), 7.33 (dd, *J* = 7.6, 8.1 Hz, 1 H, indazole), 7.18 (t, *J* = 8.7 Hz, 2 H, Ph), 7.09 (dd, *J* = 7.6, 8.4 Hz, 1 H, indazole), 6.90 (d, *J* = 8.0 Hz, 2 H, Ph), 6.75 (t, *J* = 7.2 Hz, 1 H, Ph), 3.89 (2

- 23 -

H, s, indazole-CH₂-N), 3.11 (bt, $J = 5.1$ Hz, 4 H, piperazine), 2.58 (bt, $J = 5.1$ Hz, 4 H, piperazine); MS (CI+) m/e 293 (M+H⁺); Anal. calcd for C₁₈H₂₀N₄: C, 73.94; H, 6.90; N, 19.16. Found: C, 73.89; H, 6.88; N, 18.91.

5

EXAMPLE 33-[4-Benzylpiperazin-1-ylmethyl]-1H-indazole

The title compound was prepared as a white crystalline solid following the general procedure described in EXAMPLE 1; mp 130 – 131 °C (from Et₂O); ¹H NMR (360 MHz, d₆-DMSO) δ 7.84 (d, $J = 8.1$ Hz, 1 H, indazole), 7.47 (d, $J = 8.4$ Hz, 1 H, indazole), 7.33 – 7.20 (m, 6 H, aromatic), 7.07 (t, $J = 7.4$ Hz, 1 H, indazole), 3.81 (s, 2 H, indazole-CH₂-N), 3.43 (s, 2 H, CH₂Ph), 2.43 (bs, 4 H, piperazine), 2.36 (bs, 4 H, piperazine); MS (CI+) m/e 307 (M+H⁺); Anal. calcd for C₁₉H₂₂N₄: C, 74.48; H, 7.24; N, 18.29. Found: C, 74.43; H, 7.22; N, 18.57.

15

EXAMPLE 4(±)-3-[4-Phenyl-3-methylpiperazin-1-ylmethyl]-1H-indazole

The title compound was prepared as a white crystalline solid following the general procedure described in EXAMPLE 1; mp 164.5 – 165.0 °C (from Et₂O); ¹H NMR (360 MHz, d₆-DMSO) δ 12.80 (bs, 1 H, NH), 7.91 (d, $J = 8.2$ Hz, 1 H, indazole), 7.49 (d, $J = 8.4$ Hz, 1 H, indazole), 7.33 (dd, $J = 6.0, 7.0$ Hz, 1 H, indazole), 7.18 (t, $J = 7.4$ Hz, 2 H, Ph), 7.09 (t, $J = 7.2$ Hz, 1 H, indazole), 6.85 (d, $J = 8.1$ Hz, 2 H, Ph), 6.71 (t, $J = 7.3$ Hz, 1 H,

20

25

Ph), 3.97 – 3.95 (m, 1 H, *CH*-Me), 3.85 (s, 2 H, indazole-*CH*₂-N),
3.26 – 3.21 (m, 1 H, piperazine), 2.97 – 2.84 (m, 2 H, piperazine),
2.71 – 2.68 (m, 1 H, piperazine), 2.43 – 2.39 (m, 1 H, piperazine),
2.25 – 2.18 (m, 1 H, piperazine), 0.96 (d, *J* = 5.7 Hz, 3 H, *Me*);
5 MS (CI+) *m/e* 307 (M+H⁺); Anal. calcd for C₁₉H₂₂N₄: C, 74.48;
H, 7.24; N, 18.29. Found: C, 74.53; H, 7.28; N, 18.11.

EXAMPLE 5

3-[4-(4-Fluorophenyl)piperazin-1-ylmethyl]-1*H*-indazole

Step A: 1-Acetyl-3-methyl-1*H*-indazole

10 3-Methyl-1*H*-indazole (6.157 g, 44.6 mmol) in CH₂Cl₂
(100 mL) was treated with acetic anhydride (22.75 g, 223 mmol),
triethylamine (22.5 g, 223 mmol) and DMAP (0.54 g, 4.5 mmol).
The mixture was stirred 1 h at 20 °C, poured into water (100
mL) and extracted with CH₂Cl₂ (2 x 100 mL). The extracts were
15 dried (Na₂SO₄), concentrated and the residue recrystallised
from hexane to give the title compound (4.12 g, 66%) as a white
crystalline solid; mp 70 – 71 °C (from hexane); ¹H NMR (360
MHz, CDCl₃) δ 8.41 (d, *J* = 8.4 Hz, 1 H, indazole), 7.64 (d, *J* =
8.4 Hz, 1 H, indazole), 7.54 (t, *J* = 8.4 Hz, 1 H, indazole), 7.35 (t,
20 *J* = 8.4 Hz, 1 H, indazole), 2.75 (s, 3 H, Ac), 2.58 (s, 3 H, Me);
MS (CI+) *m/e* 175 (M+H⁺); Anal. calcd for C₁₀H₁₀N₂O: C, 68.95;
H, 5.97; N, 16.08. Found: C, 68.80; H, 5.58; N, 16.18.

Step B: 1-Acetyl-3-bromomethyl-1*H*-indazole

25 1-Acetyl-3-methyl-1*H*-indazole (5.77 g, 33.1 mmol) in
CCl₄ (150 mL) was treated with *N*-bromosuccinimide (6.49 g,

36.5 mmol) and benzoyl peroxide (0.80 g, 3.3 mmol) and the mixture was heated at 70 °C for 16 h. The mixture was concentrated and the residue quickly filtered through a plug of flash silica eluting with 0 → 5% EtOAc in hexane to give the
5 crude title compound contaminated with traces of dibromide and starting material. This was conveniently used directly in subsequent reactions without further purification.

Step C: 1-Acetyl-3-[4-(4-fluorophenyl)piperazin-1-ylmethyl]-1H-indazole

10 1-Acetyl-3-bromomethyl-1H-indazole (160 mg, 0.63 mmol) in CH₂Cl₂ (5 mL) was treated with 1-(4-fluorophenyl)piperazine (228 mg, 1.26 mmol) and Hünig's base (102 mg, 0.79 mmol) and the mixture stirred at 20 °C for 16 h. The mixture was poured into saturated aqueous sodium
15 bicarbonate solution (10 mL) and extracted with CH₂Cl₂ (3 x 10 mL). The combined organic extracts were dried (MgSO₄), concentrated and the residue purified by flash chromatography (10% → 25% EtOAc in hexane) to give the title compound as a white solid. This was recrystallised from ether / hexane to give
20 colourless crystals (184 mg, 83%); mp 119 – 120 °C (from ether / hexane); ¹H NMR (360 MHz, d₆-DMSO) δ 8.31 (d, *J* = 8.3 Hz, 1 H, indazole), 8.08 (d, *J* = 8.3 Hz, 1 H, indazole), 7.63 (t, *J* = 8.3 Hz, 1 H, indazole), 7.43 (t, *J* = 8.3 Hz, 1 H, indazole), 7.03 (m, 2 H, Ph), 6.93 (m, 2 H, Ph), 3.95 (s, 2 H, Ar-CH₂N), 3.08 (m, 4 H,
25 piperazine), 2.70 (s, 3 H, Ac), 2.64 (m, 4 H, piperazine); MS (CI+) *m/e* 353 (M+H⁺); Anal. calcd for C₂₀H₂₁N₄OF: C, 68.16; H, 6.01; N, 15.90. Found: C, 68.15; H, 5.85; N, 15.64.

Step D: 3-[4-(4-Fluorophenyl)piperazin-1-ylmethyl]-1H-indazole

1-Acetyl-3-[4-(4-fluorophenyl)piperazin-1-ylmethyl]-1H-indazole (112 mg, 0.32 mmol) in MeOH (3 mL) was treated with sodium methoxide (50 mg) and stirred for 1 h at 20 °C. The mixture was poured into saturated aqueous sodium bicarbonate solution (5 mL) and extracted with CH₂Cl₂ (3 x 5 mL). The combined organic extracts were dried (MgSO₄), concentrated and the residue purified by flash chromatography (10 → 100% EtOAc in hexane) to give the title compound as a white solid (52 mg, 52%); mp 191 – 192 °C (from CH₂Cl₂ / hexane); ¹H NMR (360 MHz, d₆-DMSO) δ 12.85 (bs, 1 H, NH), 7.88 (d, *J* = 8.9 Hz, 1 H, indazole), 7.49 (d, *J* = 8.9 Hz, 1 H, indazole), 7.33 (t, *J* = 8.9 Hz, 1 H, indazole), 7.09 (t, *J* = 8.9 Hz, 1 H, indazole), 7.00 (m, 2 H, Ph), 6.92 (m, 2 H, Ph), 3.89 (s, 2 H, Ar-CH₂N), 3.06 (m, 4 H, piperazine), 2.58 (m, 4 H, piperazine); MS (CI+) *m/e* 311 (M+H⁺); Anal. calcd for C₁₈H₁₉N₄F.¼ H₂O: C, 68.66; H, 6.24; N, 17.79. Found: C, 68.75; H, 6.13; N, 17.74.

EXAMPLE 6

3-[4-(2-Methylphenyl)piperazin-1-ylmethyl]-1H-indazole

The title compound was prepared as a white crystalline solid following the general procedure described in EXAMPLE 5; mp 135 – 136 °C (from ether / hexane); ¹H NMR (360 MHz, d₆-DMSO) δ 12.82 (bs, 1 H, NH), 7.89 (d, *J* = 8.2 Hz, 1 H, indazole), 7.49 (d, *J* = 8.2 Hz, 1 H, indazole), 7.33 (t, *J* = 8.2 Hz, 1 H, indazole), 7.12 (t, *J* = 8.2 Hz, 1 H, indazole), 7.10 (m, 2 H, Ph), 6.99 (d, *J* = 7.5 Hz, 1 H, Ph), 6.92 (t, *J* = 7.5 Hz, 1 H, Ph),

- 27 -

3.90 (s, 2 H, Ar-CH₂N), 2.82 (m, 4 H, piperazine), 2.60 (bs, 4 H, piperazine), 2.21 (s, 3 H, Me); MS (CI+) *m/e* 307 (M+H⁺); Anal. calcd for C₁₉H₂₂N₄: C, 74.48; H, 7.24; N, 18.29. Found: C, 74.18; H, 7.28; N, 18.37.

5

EXAMPLE 73-[4-(3-Methylphenyl)piperazin-1-ylmethyl]-1H-indazole

The title compound was prepared as a white crystalline solid following the general procedure described in EXAMPLE 5; mp 132 – 134 °C (from CH₂Cl₂ / hexane); ¹H NMR (360 MHz, d₆-DMSO) δ 12.83 (bs, 1 H, NH), 7.88 (d, *J* = 8.1 Hz, 1 H, indazole), 7.48 (d, *J* = 8.1 Hz, 1 H, indazole), 7.33 (t, *J* = 8.1 Hz, 1 H, indazole), 7.09 (t, *J* = 8.1 Hz, 1 H, indazole), 7.06 (t, *J* = 7.8 Hz, 1 H, Ph), 6.72 (s, 1 H, Ph), 6.69 (d, *J* = 7.8 Hz, 1 H, Ph), 6.57 (d, *J* = 7.8 Hz, 1 H, Ph), 3.88 (s, 2 H, Ar-CH₂N), 3.09 (m, 4 H, piperazine), 2.56 (m, 4 H, piperazine), 2.22 (s, 3 H, Me); MS (CI+) *m/e* 307 (M+H⁺); Anal. calcd for C₁₉N₂₂N₄: C, 74.48; H, 7.24; N, 18.29. Found: C, 74.05; H, 7.24; N, 18.28.

EXAMPLE 83-[4-(4-Methylphenyl)piperazin-1-ylmethyl]-1H-indazole

The title compound was prepared as a white crystalline solid following the general procedure described in EXAMPLE 5; mp 176 – 177 °C (from ether / hexane); ¹H NMR (360 MHz, d₆-DMSO) δ 12.82 (bs, 1 H, NH), 7.88 (d, *J* = 8.1 Hz, 1 H, indazole), 7.48 (d, *J* = 8.1 Hz, 1 H, indazole), 7.33 (t, *J* = 8.1 Hz, 1 H, indazole), 7.09 (t, *J* = 8.1 Hz, 1 H, indazole), 6.98 (d, *J* = 8.6

Hz, 2 H, Ph), 6.80 (d, $J = 8.6$ Hz, 2 H, Ph), 3.88 (s, 2 H, Ar-CH₂N), 3.04 (m, 4 H, piperazine), 2.50 (m, 4 H, piperazine), 2.18 (s, 3 H, Me); MS (CI+) m/e 307 (M+H⁺); Anal. calcd for C₁₉N₂₂N₄: C, 74.48; H, 7.24; N, 18.29. Found: C, 74.30; H, 7.27; N, 18.27.

EXAMPLE 9

3-[4-(2-Pyrimidyl)piperazin-1-ylmethyl]-1H-indazole

The title compound was prepared as a white crystalline solid following the general procedure described in EXAMPLE 5; mp 129 – 130 °C (from ether / hexane); ¹H NMR (360 MHz, d₆-DMSO) δ 12.82 (bs, 1 H, NH), 8.33 (d, $J = 4.6$ Hz, 2 H, pyrimidine), 7.89 (d, $J = 8.0$ Hz, 1 H, indazole), 7.48 (d, $J = 8.0$ Hz, 1 H, indazole), 7.33 (t, $J = 8.0$ Hz, 1 H, indazole), 7.10 (t, $J = 8.0$ Hz, 1 H, indazole), 6.59 (t, $J = 4.6$ Hz, 1 H, pyrimidine), 3.87 (s, 2 H, Ar-CH₂N), 3.71 (m, 4 H, piperazine), 2.49 (m, 4 H, piperazine); MS (CI+) m/e 295 (M+H⁺); Anal. calcd for C₁₆H₁₈N₆: C, 65.29; H, 6.16; N, 28.55. Found: C, 65.22; H, 6.15; N, 28.40.

EXAMPLE 10

3-[4-Piperonylpiperazin-1-ylmethyl]-1H-indazole

The title compound was prepared as a white crystalline solid following the general procedure described in EXAMPLE 5; mp 175 – 176 °C (from CH₂Cl₂ / hexane); ¹H NMR (360 MHz, d₆-DMSO) δ 12.77 (bs, 1 H, NH), 7.83 (d, $J = 8.1$ Hz, 1 H, indazole), 7.46 (d, $J = 8.1$ Hz, 1 H, indazole), 7.31 (t, $J = 8.1$ Hz,

- 29 -

1 H, indazole), 7.07 (t, $J = 8.1$ Hz, 1 H, indazole), 6.81 (s, 1 H, piperonyl), 6.81 (d, $J = 8.0$ Hz, 1 H, piperonyl), 6.70 (d, $J = 8.0$ Hz, 1 H, piperonyl), 5.97 (s, 2 H, O-CH₂-O), 3.81 (s, 2 H, indazole-CH₂N), 3.34 (s, 2 H, Ph-CH₂N), 2.42 (bs, 4 H, piperazine), 2.34 (bs, 4 H, piperazine); MS (CI+) m/e 351 (M+H⁺); Anal. calcd for C₂₀H₂₂N₄O₂· $\frac{1}{4}$ H₂O: C, 67.68; H, 6.39; N, 15.78. Found: C, 67.98; H, 6.25; N, 15.85.

EXAMPLE 11

10 3-[4-(3-Trifluoromethylphenyl)piperazin-1-ylmethyl]-1H-indazole

The title compound was prepared as a white crystalline solid following the general procedure described in EXAMPLE 5; mp 78 – 80 °C (from ether / hexane); ¹H NMR (360 MHz, d₆-DMSO) δ 12.84 (bs, 1 H, NH), 7.89 (d, $J = 8.1$ Hz, 1 H, indazole), 7.49 (d, $J = 8.1$ Hz, 1 H, indazole), 7.39 (t, $J = 8.1$ Hz, 1 H, Ph), 7.33 (t, $J = 8.1$ Hz, 1 H, indazole), 7.19 (d, $J = 8.1$ Hz, 1 H, Ph), 7.13 (s, 1 H, Ph), 7.09 (t, $J = 8.1$ Hz, 1 H, indazole), 7.04 (d, $J = 8.1$ Hz, 1 H, Ph), 3.90 (s, 2 H, Ar-CH₂N), 3.21 (m, 4 H, piperazine), 2.59 (m, 4 H, piperazine); MS (CI+) m/e 361 (M+H⁺); Anal. calcd for C₁₉H₁₉N₄F₃· $\frac{1}{4}$ H₂O: C, 62.54; H, 5.39; N, 15.35. Found: C, 62.70; H, 5.32; N, 15.39.

EXAMPLE 12

3-[4-(2-Pyridyl)piperazin-1-ylmethyl]-1H-indazole

25 The title compound was prepared as a white crystalline solid following the general procedure described in EXAMPLE 5;

- 30 -

mp 148 – 150 °C (from CH₂Cl₂ / hexane); ¹H NMR (360 MHz, d₆-DMSO) δ 12.83 (bs, 1 H, NH), 8.08 (m, 1 H, pyridyl), 7.89 (d, *J* = 8.1 Hz, 1 H, indazole), 7.50 (m, 1 H, pyridyl), 7.48 (d, *J* = 8.1 Hz, 1 H, indazole), 7.33 (t, *J* = 8.1 Hz, 1 H, indazole), 7.09 (t, *J* = 8.1 Hz, 1 H, indazole), 6.78 (d, *J* = 8.6 Hz, 1 H, pyridyl), 6.6.1 (m, 1 H, pyridyl), 3.88 (s, 2 H, Ar-CH₂N), 3.46 (m, 4 H, piperazine), 2.52 (m, 4 H, piperazine); MS (CI+) *m/e* 294 (M+H⁺); Anal. calcd for C₁₇H₁₉N₅·¼ H₂O: C, 68.55; H, 6.60; N, 23.51. Found: C, 68.29; H, 6.36; N, 23.19.

10

EXAMPLE 133-[4-(4-Methoxyphenyl)piperazin-1-ylmethyl]-1*H*-indazole

The title compound was prepared as a white crystalline solid following the general procedure described in EXAMPLE 5; mp 167 – 168 °C (from EtOAc); ¹H NMR (360 MHz, d₆-DMSO) δ 12.82 (bs, 1 H, NH), 7.87 (d, *J* = 8.1 Hz, 1 H, indazole), 7.48 (d, *J* = 8.1 Hz, 1 H, indazole), 7.33 (t, *J* = 8.1 Hz, 1 H, indazole), 7.09 (t, *J* = 8.1 Hz, 1 H, indazole), 6.86 (d, *J* = 9.2 Hz, 2 H, Ph), 6.79 (d, *J* = 9.2 Hz, 2 H, Ph), 3.88 (s, 2 H, Ar-CH₂N), 3.67 (s, 3 H, OMe), 2.99 (m, 4 H, piperazine), 2.57 (m, 4 H, piperazine); MS (CI+) *m/e* 323 (M+H⁺); Anal. calcd for C₁₉H₂₂N₄O: C, 70.78; H, 6.88; N, 17.38. Found: C, 70.72; H, 6.93; N, 17.33.

EXAMPLE 143-[4-(4-Acetylphenyl)piperazin-1-ylmethyl]-1H-indazole

The title compound was prepared as a white crystalline solid following the general procedure described in EXAMPLE 5; mp 198 – 200 °C (from EtOAc); ¹H NMR (360 MHz, d₆-DMSO) δ 12.84 (bs, 1 H, NH), 7.88 (d, *J* = 8.1 Hz, 1 H, indazole), 7.68 (d, *J* = 9.7 Hz, 2 H, Ph), 7.49 (d, *J* = 8.1 Hz, 1 H, indazole), 7.33 (t, *J* = 8.1 Hz, 1 H, indazole), 7.09 (t, *J* = 8.1 Hz, 1 H, indazole), 6.94 (d, *J* = 9.7 Hz, 2 H, Ph), 3.89 (s, 2 H, Ar-CH₂N), 3.33 (m, 4 H, piperazine), 2.57 (m, 4 H, piperazine), 2.44 (s, 3 H, Me); MS (CI+) *m/e* 335 (M+H⁺); Anal. calcd for C₂₀H₂₂N₄O: C, 71.83; H, 6.63; N, 16.75. Found: C, 72.03; H, 6.54; N, 16.71.

EXAMPLE 153-[4-(5-Methylpyridin-2-yl)piperazin-1-ylmethyl]-1H-indazole

The title compound was prepared as a white crystalline solid following the general procedure described in EXAMPLE 5; mp 151 – 153 °C (from EtOAc); ¹H NMR (360 MHz, d₆-DMSO) δ 12.82 (bs, 1 H, NH), 7.92 (s, 1 H, pyridine), 7.88 (d, *J* = 8.0 Hz, 1 H, indazole), 7.48 (d, *J* = 8.0 Hz, 1 H, indazole), 7.34 (t, *J* = 8.0 Hz, 1 H, indazole), 7.33 (m, 1 H, pyridine), 7.09 (t, *J* = 8.0 Hz, 1 H, indazole), 6.71 (d, *J* = 8.6 Hz, 1 H, pyridine), 3.87 (s, 2 H, Ar-CH₂N), 3.39 (m, 4 H, piperazine), 2.51 (m, 4 H, piperazine), 2.12 (s, 3 H, Me); MS (CI+) *m/e* 308 (M+H⁺); Anal. calcd for C₁₈H₂₁N₅: C, 70.33; H, 6.87; N, 22.78. Found: C, 70.48; H, 6.91; N, 22.89.

EXAMPLE 163-(4-Benzof[1,3]dioxol-5-yl)piperazin-1-ylmethyl)-1H-indazole

The title compound was prepared as a white crystalline solid following the general procedure described in EXAMPLE 5; mp 149 – 150 °C (from EtOAc); ¹H NMR (360 MHz, d₆-DMSO) δ 12.79 (bs, 1 H, NH), 7.87 (d, *J* = 8.1 Hz, 1 H, indazole), 7.48 (d, *J* = 8.1 Hz, 1 H, indazole), 7.32 (t, *J* = 8.1 Hz, 1 H, indazole), 7.09 (t, *J* = 8.1 Hz, 1 H, indazole), 6.72 (d, *J* = 8.4 Hz, 1 H, Ph), 6.83 (d, *J* = 2.3 Hz, 1 H, Ph), 6.30 (dd, *J* = 8.4, 2.3 Hz, 1 H, Ph), 5.88 (s, 2 H, O-CH₂-O), 3.87 (s, 2 H, Ar-CH₂N), 2.99 (m, 4 H, piperazine), 2.54 (m, 4 H, piperazine); MS (CI+) *m/e* 337 (M+H⁺); Anal. calcd for C₁₉H₂₀N₄O₂·¼ H₂O: C, 66.94; H, 6.06; N, 16.44. Found: C, 67.21; H, 5.93; N, 16.10.

EXAMPLE 173-[4-(3,5-Bis-trifluoromethylphenyl)piperazin-1-ylmethyl]-1H-indazole

The title compound was prepared as a white crystalline solid following the general procedure described in EXAMPLE 5; mp 155 – 156 °C (from EtOAc); ¹H NMR (360 MHz, d₆-DMSO) δ 12.85 (bs, 1 H, NH), 7.89 (d, *J* = 8.1 Hz, 1 H, indazole), 7.49 (d, *J* = 8.1 Hz, 1 H, indazole), 7.43 (s, 2 H, Ph), 7.33 (t, *J* = 8.1 Hz, 1 H, indazole), 7.28 (s, 1 H, Ph), 7.09 (t, *J* = 8.1 Hz, 1 H, indazole), 3.90 (s, 2 H, Ar-CH₂N), 3.34 (m, 4 H, piperazine), 2.59 (m, 4 H, piperazine); MS (CI+) *m/e* 429 (M+H⁺); Anal. calcd for

C₂₀H₁₈N₄F₆: C, 56.08; H, 4.24; N, 13.08. Found: C, 56.45; H, 4.16; N, 12.63.

EXAMPLE 18

5 3-[4-(5-Trifluoromethylpyridin-2-yl)piperazin-1-ylmethyl]-1H-indazole dihydrochloride

The title compound was prepared as a white crystalline solid following the general procedure described in EXAMPLE 5; mp 150 – 152 °C (from EtOAc); ¹H NMR (360 MHz, d₆-DMSO) δ 13.55 (bs, 1 H, NH), 10.68 (bs, 2 H, NH⁺), 8.47 (s, 1 H, pyridine), 10 8.00 (d, *J* = 8.1 Hz, 1 H, indazole), 7.91 (d, *J* = 9.1 Hz, 1 H, pyridine), 7.61 (d, *J* = 8.1 Hz, 1 H, indazole), 7.44 (t, *J* = 8.1 Hz, 1 H, indazole), 7.24 (t, *J* = 8.1 Hz, 1 H, indazole), 7.06 (d, *J* = 9.1 Hz, 1 H, pyridine), 4.77 (s, 2 H, Ar-CH₂N), 4.54 (m, 2 H, piperazine), 3.66 – 3.09 (m, 6 H, piperazine); MS (CI⁺) *m/e* 362 15 (M+H⁺); Anal. calcd for C₁₈H₁₈F₃N₅·2HCl·5/2 H₂O: C, 45.53; H, 5.20; N, 14.75. Found: C, 45.65; H, 5.05; N, 14.37.

EXAMPLE 19

20 3-[4-(4-Trifluoromethylpyridin-2-yl)piperazin-1-ylmethyl]-1H-indazole

The title compound was prepared as a white crystalline solid following the general procedure described in EXAMPLE 5; mp 99 – 100 °C (from EtOAc); ¹H NMR (360 MHz, d₆-DMSO) δ 12.81 (bs, 1 H, NH), 8.30 (d, *J* = 5.0 Hz, 1 H, pyridine), 7.89 (d, *J* = 8.0 Hz, 1 H, indazole), 7.48 (d, *J* = 8.1 Hz, 1 H, indazole), 7.33 25 (t, *J* = 8.1 Hz, 1 H, indazole), 7.09 (t, *J* = 8.1 Hz, 1 H, indazole),

- 34 -

7.04 (s, 1 H, pyridine), 6.85 (d, $J = 5.0$ Hz, 1 H, pyridine), 3.89 (s, 2 H, Ar-CH₂N), 3.58 (m, 4 H, piperazine), 2.51 (m, 4 H, piperazine); MS (CI+) m/e 362 (M+H⁺); Anal. calcd for C₁₈H₁₈F₃N₅·½ H₂O: C, 58.37; H, 5.17; N, 18.91. Found: C, 58.47; H, 5.23; N, 18.66.

EXAMPLE 20

3-[4-(5-Chloropyridin-2-yl)piperazin-1-ylmethyl]-1H-indazole

The title compound was prepared as a white crystalline solid following the general procedure described in EXAMPLE 5; mp 203 – 204 °C (from EtOAc); ¹H NMR (360 MHz, d₆-DMSO) δ 12.83 (bs, 1 H, NH), 8.08 (d, $J = 2.7$ Hz, 1 H, pyridine), 7.88 (d, $J = 8.1$ Hz, 1 H, indazole), 7.56 (dd, $J = 9.1, 2.7$ Hz, 1 H, pyridine), 7.48 (d, $J = 8.1$ Hz, 1 H, indazole), 7.33 (t, $J = 8.1$ Hz, 1 H, indazole), 7.09 (t, $J = 8.1$ Hz, 1 H, indazole), 6.83 (d, $J = 9.1$ Hz, 1 H, pyridine), 3.88 (s, 2 H, Ar-CH₂N), 3.46 (m, 4 H, piperazine), 2.51 (m, 4 H, piperazine); MS (CI+) m/e 328 (M+H⁺); Anal. calcd for C₁₇H₁₈ClN₅: C, 62.29; H, 5.53; N, 21.36. Found: C, 62.14; H, 5.36; N, 21.34.

20

EXAMPLE 21

3-[4-(5-Methoxypyridin-2-yl)piperazin-1-ylmethyl]-1H-indazole

The title compound was prepared as a white crystalline solid following the general procedure described in EXAMPLE 5; mp 132 – 134 °C (from EtOAc); mp 132 – 134 °C (from EtOAc);

25

5 ^1H NMR (360 MHz, d_6 -DMSO) δ 12.82 (bs, 1 H, NH), 7.88 (d, J = 8.2 Hz, 1 H, indazole), 7.86 (d, J = 3.0 Hz, 1 H, pyridine), 7.48 (d, J = 8.2 Hz, 1 H, indazole), 7.33 (t, J = 8.2 Hz, 1 H, indazole), 7.23 (dd, J = 9.1, 3.0 Hz, 1 H, pyridine), 7.09 (t, J = 8.2 Hz, 1 H, indazole), 6.77 (d, J = 9.1 Hz, 1 H, pyridine), 3.87 (s, 2 H, Ar-CH₂N), 3.71 (s, 3 H, OMe), 3.32 (m, 4 H, piperazine), 2.53 (m, 4 H, piperazine); MS (CI+) m/e 324 (M+H⁺); Anal. calcd for C₁₈H₂₁N₅O: C, 66.85; H, 6.55; N, 21.66. Found: C, 66.51; H, 6.53; N, 21.33.

10

EXAMPLE 222-[4-(1H-Indazol-3-ylmethyl)piperazin-1-yl]quinoline

The title compound was prepared as a white crystalline solid following the general procedure described in EXAMPLE 5; mp 187 – 188 °C (from EtOAc); ^1H NMR (360 MHz, d_6 -DMSO) δ 12.83 (bs, 1 H, NH), 8.01 (d, J = 9.2 Hz, 1 H, quinoline), 7.90 (d, J = 8.1 Hz, 1 H, indazole), 7.67 (d, J = 8.1 Hz, 1 H, indazole), 7.52 (t, J = 8.1 Hz, 1 H, indazole), 7.50 (m, 2 H, quinoline), 7.33 (t, J = 8.1 Hz, 1 H, indazole), 7.20 (m, 2 H, quinoline), 7.10 (t, J = 7.5 Hz, 1 H, quinoline), 3.90 (s, 2 H, Ar-CH₂N), 3.68 (m, 4 H, piperazine), 3.57 (m, 4 H, piperazine); MS (CI+) m/e 344 (M+H⁺); Anal. calcd for C₂₁H₂₁N₅: C, 73.44; H, 6.16; N, 20.39. Found: C, 72.99; H, 6.11; N, 20.22.

EXAMPLE 233-[4-(1H-Indazol-3-ylmethyl)piperazin-1-yl]isoquinoline

The title compound was prepared as a bright yellow crystalline solid following the general procedure described in
5 EXAMPLE 5; mp 214 – 215 °C (from EtOAc); ¹H NMR (360 MHz, d₆-DMSO) δ 12.83 (bs, 1 H, NH), 7.90 (d, *J* = 8.1 Hz, 1 H, indazole), 7.85 (d, *J* = 8.2 Hz, 1 H, isoquinoline), 7.64 (d, *J* = 8.4 Hz, 1 H, indazole), 7.52 (t, *J* = 8.1 Hz, 1 H, indazole), 7.49 (d, *J* = 8.7 Hz, 1 H, isoquinoline), 7.33 (t, *J* = 8.1 Hz, 1 H, indazole),
10 7.28 (t, *J* = 7.3 Hz, 1 H, isoquinoline), 7.10 (t, *J* = 7.2 Hz, 1 H, isoquinoline), 6.94 (s, 1 H, isoquinoline), 3.91 (s, 2 H, Ar-CH₂N), 3.53 (m, 4 H, piperazine), 2.60 (m, 4 H, piperazine); MS (CI+) *m/e* 344 (M+H⁺); Anal. calcd for C₂₁H₂₁N₅·¼ H₂O: C, 72.49; H, 6.23; N, 20.13. Found: C, 72.72; H, 6.06; N, 20.21.

15

EXAMPLE 246-Fluoro-3-[4-(4-methoxyphenyl)piperazin-1-ylmethyl]-1H-indazoleStep A: 1-(2-Amino-4-fluorophenyl)ethanone

A solution of BCl₃ (110 mL of a 1.0 M solution in
20 CH₂Cl₂, 110 mmol) was cooled to 0 °C and treated with a solution of 3-fluoroaniline (10 mL, 104 mmol) in 1,1,2,2-tetrachloroethane (200 mL). The resulting solution was stirred 15 min and treated with MeCN (16.3 mL, 330 mmol) and AlCl₃ (14.7 g, 110 mmol) and heated at 120 °C for 16 h with
25 distillative removal of CH₂Cl₂. The mixture was cooled to 0 °C

and quenched with 2 M aqueous HCl (250 mL). The mixture was heated at 80 °C for 1 h to hydrolyse the imine, and extracted with CH₂Cl₂ (5 x 100 mL). The combined organic extracts were dried (MgSO₄), concentrated and purified by flash chromatography (10% EtOAc in hexane) to give the title compound (9.618 g, 60%) as a low melting pale yellow crystalline solid; ¹H NMR (360 MHz, d₆-DMSO) δ 7.81 (dd, *J* = 8.9, 6.7 Hz, 1 H, Ph), 7.43 (bs, 2 H, NH₂), 6.49 (dd, *J* = 12.0, 2.6 Hz, 1 H, Ph), 6.35 (dt, *J* = 8.9, 0.7 Hz, 1 H, Ph), 2.48 (s, 3 H, Me).

Step B: 6-Fluoro-3-methyl-1*H*-indazole

1-(2-Amino-4-fluorophenyl)ethanone (9.618 g, 62.9 mmol) was treated with concentrated hydrochloric acid (16 mL) and water (16 mL), and the resulting white suspension was cooled to -10 °C and treated with a solution of sodium nitrite (4.338 g, 62.9 mmol) in 10 mL H₂O, maintaining the temperature below 0 °C. The resulting solution was filtered directly into a rapidly stirred solution of SnCl₂·2H₂O (34 g in 200 mL H₂O) and the resulting mixture was stirred for 1 h at 20 °C, basified (32 g NaOH in 200 mL H₂O) and extracted with EtOAc. The combined organic extracts were dried (MgSO₄), concentrated and the residue purified by flash chromatography (25% EtOAc in hexane) to give the title compound (3.10 g, 33%) as a white solid; mp 116 – 117 °C (from hexane); ¹H NMR (360 MHz, CDCl₃) δ 12.89 (bs, 1 H, NH), 7.62 (dd, *J* = 8.8, 5.1 Hz, 1 H, indazole), 7.09 (dd, *J* = 9.1, 2.0 Hz, 1 H, indazole), 6.93 (dt, *J* = 9.1, 2.0 Hz, 1 H, indazole), 2.60 (s, 3 H, Me); MS (CI+) *m/e* 151 (M+H⁺); Anal. calcd for C₈H₇FN₂: C, 63.99, H, 4.70; N, 18.66. Found: C, 63.94; H, 4.72; N, 19.10.

Step C: 1-Acetyl-6-fluoro-3-methyl-1H-indazole

6-Fluoro-3-methyl-1H-indazole (2.79 g, 18.6 mmol) in CH₂Cl₂ (50 mL) was treated with acetic anhydride (2.8 g, 30 mmol), Hünig's base (5.2 mL, 30 mmol) and DMAP (0.2 g, 1.7 mmol). The mixture was stirred 1 h at 20 °C, poured into water (100 mL) and extracted with CH₂Cl₂ (2 x 100 mL). The extracts were dried (Na₂SO₄), concentrated and the residue recrystallised from hexane to give the title compound (3.41 g, 96%) as a white crystalline solid; mp 89 – 91 °C (from hexane); ¹H NMR (360 MHz, CDCl₃) δ 8.05 (dd, *J* = 9.4, 2.2 Hz, 1 H, indazole), 7.51 (dd, *J* = 8.7, 5.1 Hz, 1 H, indazole), 7.03 (dt, *J* = 8.8, 2.2 Hz, 1 H, indazole), 2.67 (s, 3 H, Me), 2.49 (s, 3 H, Ac); MS (CI+) *m/e* 193 (M+H⁺); Anal. calcd for C₁₀H₉FN₂O: C, 62.49; H, 4.72; N, 14.58. Found: C, 62.50; H, 4.79; N, 14.63.

Step D: 1-Acetyl-3-bromomethyl-6-fluoro-1H-indazole

1-Acetyl-6-fluoro-3-methyl-1H-indazole (5.77 g, 33.1 mmol) in CCl₄ (100 mL) was treated with NBS (3.64 g, 20 mmol) and benzoyl peroxide (0.388 g, 1.6 mmol) and the mixture was heated at 70 °C for 6 h. The mixture was concentrated and the residue quickly filtered through a plug of flash silica eluting with 2% → 7% EtOAc in hexane to give the crude title compound (2.97 g, 65%) contaminated with traces of dibromide and starting material. This was conveniently used directly in subsequent reactions without further purification.

1-Acetyl-3-bromomethyl-6-chloro-1H-indazole, 1-acetyl-3-bromomethyl-7-iodo-1H-indazole, 1-acetyl-3-bromomethyl-7-fluoro-1H-indazole, 1-acetyl-3-bromomethyl-6,7-difluoro-1H-

indazole, and 1-acetyl-3-bromomethyl-7-chloro-1*H*-indazole were similarly prepared from 3-chloroaniline, 2-iodoaniline, 2-fluoroaniline, 2,3-difluoroaniline and 2-chloroaniline, respectively.

5 Step E: 1-Acetyl-6-fluoro-3-[4-(4-methoxyphenyl)piperazin-1-ylmethyl]-1*H*-indazole

1-Acetyl-3-bromomethyl-6-fluoro-1*H*-indazole (0.63 g, 2.33 mmol) in CH₂Cl₂ (10 mL) was treated with 4-methoxyphenylpiperazine dihydrochloride (0.593 g, 2.33 mmol) and Hünig's base (1.32 mL, 7.5 mmol) and the mixture stirred at 10 20 °C for 16 h. The mixture was poured into saturated aqueous sodium bicarbonate solution (25 mL) and extracted with CH₂Cl₂ (3 x 25 mL). The combined organic extracts were dried (MgSO₄), concentrated and the residue purified by flash chromatography 15 (25% EtOAc in hexane) to give the title compound as a white solid (475 mg, 53%); mp 94 – 95 °C (from Et₂O / hexane); ¹H NMR (360 MHz, d₆-DMSO) δ 8.12 (dd, *J* = 8.4, 2.9 Hz, 1 H, indazole), 8.00 (d, *J* = 9.8 Hz, 1 H, indazole), 7.34 (t, *J* = 9.8 Hz, 1 H, indazole), 6.87 (d, *J* = 9.2 Hz, 2 H, Ph), 6.80 (d, *J* = 9.2 Hz, 20 2 H, Ph), 3.93 (s, 2 H, Ar-CH₂N), 3.67 (s, 3 H, OMe), 3.02 (m, 4 H, piperazine), 2.70 (s, 3 H, Ac), 2.63 (m, 4 H, piperazine); MS (CI+) *m/e* 383 (M+H⁺); Anal. calcd for C₂₁H₂₃FN₄O₂: C, 65.95; H, 6.06; N, 14.65. Found: C, 66.38; H, 5.79; N, 14.59.

25 Step F: 6-Fluoro-3-[4-(4-methoxyphenyl)piperazin-1-ylmethyl]-1*H*-indazole

1-Acetyl-6-fluoro-3-[4-(4-methoxyphenyl)piperazin-1-ylmethyl]-1*H*-indazole (445 mg, 1.16 mmol) in CH₂Cl₂ / MeOH

- 40 -

(1:1, 25 mL) was treated with sodium methoxide (2 mg) and stirred for 15 min at 20 °C. The mixture was poured into saturated aqueous sodium bicarbonate solution (25 mL) and extracted with CH₂Cl₂ (3 x 50 mL). The combined organic
5 extracts were dried (MgSO₄), concentrated and the residue recrystallised from EtOAc / hexane to give the title compound as colourless crystals (290 mg, 73%); mp 155 – 156 °C (from EtOAc / hexane); ¹H NMR (360 MHz, d₆-DMSO) δ 12.89 (bs, 1 H, NH), 7.90 (dd, *J* = 8.9, 5.5 Hz, 1 H, indazole), 7.25 (dd, *J* = 9.7, 2.1 Hz,
10 1 H, indazole), 6.97 (dt, *J* = 9.3, 2.2 Hz, 1 H, indazole), 6.86 (d, *J* = 9.2 Hz, 2 H, Ph), 6.79 (d, *J* = 9.2 Hz, 2 H, Ph), 3.86 (s, 2 H, Ar-CH₂N), 3.67 (s, 3 H, OMe), 2.99 (m, 4 H, piperazine), 2.56 (m, 4 H, piperazine); MS (CI+) *m/e* 341 (M+H⁺); Anal. calcd for C₁₉H₂₁FN₄O: C, 67.04; H, 6.22; N, 16.46. Found: C, 67.01; H,
15 5.99; N, 16.36.

EXAMPLE 25

3-[4-(4-Chlorophenyl)piperazin-1-ylmethyl]-6-fluoro-1H-indazole

The title compound was prepared as a white crystalline
20 solid following the general procedure described in EXAMPLE 24; mp 217 – 219 °C (from EtOAc / hexane); ¹H NMR (360 MHz, d₆-DMSO) δ 12.90 (bs, 1 H, NH), 7.90 (dd, *J* = 8.9, 5.5 Hz, 1 H, indazole), 7.25 (dd, *J* = 9.7, 2.1 Hz, 1 H, indazole), 7.20 (d, *J* = 9.1 Hz, 2 H, Ph), 6.97 (dt, *J* = 9.3, 2.2 Hz, 1 H, indazole), 6.91 (d,
25 *J* = 9.1 Hz, 2 H, Ph), 3.86 (s, 2 H, Ar-CH₂N), 3.11 (m, 4 H, piperazine), 2.56 (m, 4 H, piperazine); MS (CI+) *m/e* 345 (M+H⁺); Anal. calcd for C₁₈H₁₈N₄ClF: C, 62.7; H, 5.26; N, 16.26. Found: C, 62.85; H, 5.17; N, 16.11.

EXAMPLE 266-Fluoro-3-[4-(2-phenylacetyl)piperazin-1-ylmethyl]-1H-indazole

The title compound was prepared as a white crystalline solid following the general procedure described in EXAMPLE 24; mp 173 – 174 °C (from EtOAc); ¹H NMR (360 MHz, d₆-DMSO) δ 12.89 (bs, 1 H, NH), 7.87 (dd, *J* = 8.8, 5.4 Hz, 1 H, indazole), 7.30 – 7.18 (m, 6 H, aromatic), 6.96 (dt, *J* = 9.3, 2.2 Hz, 1 H, indazole), 3.80 (s, 2 H, Ar-CH₂N), 3.68 (s, 2 H, CH₂-Ph), 3.45 (bs, 4 H, piperazine), 2.33 (m, 4 H, piperazine); MS (CI+) *m/e* 353 (M+H⁺); Anal. calcd for C₂₀H₂₁FN₄O: C, 68.16; H, 6.01; N, 15.90. Found: C, 68.17; H, 6.12; N, 15.64.

EXAMPLE 276-Fluoro-3-[4-(2-phenylethyl)piperazin-1-ylmethyl]-1H-indazole

A solution of 6-fluoro-3-[4-(2-phenylacetyl)piperazin-1-ylmethyl]-1H-indazole (156 mg, 0.44 mmol) in THF (5 mL) was treated with LiAlH₄ (0.44 mL of a 1.0 M solution in THF, 0.44 mmol) and heated at 40 °C for 16 h. The solution was cooled, diluted with EtOAc (50 mL), 2 M aqueous NaOH was added (200 mL) and the resulting suspension was stirred for 1 h at 20 °C, filtered, concentrated and the residue purified by flash chromatography (EtOAc → 10% MeOH in EtOAc) to give the title compound (130 mg, 87%) as a white solid; mp 148 – 149 °C (from Et₂O / hexane); ¹H NMR (360 MHz, d₆-DMSO) δ 12.85

- 42 -

(bs, 1 H, NH), 7.89 (dd, $J = 8.9, 5.5$ Hz, 1 H, indazole), 7.28 – 7.14 (m, 6 H, aromatic), 6.96 (dt, $J = 9.3, 2.2$ Hz, 1 H, indazole), 3.79 (s, 2 H, Ar-CH₂N), 2.70 (t, $J = 7.2$ Hz, 2 H, CH₂-Ph), 2.51 – 2.40 (m, 10 H, piperazine, CH₂); MS (CI+) m/e 339 (M+H⁺);
5 Anal. calcd for C₂₀H₂₃FN₄: C, 70.98; H, 6.85, N, 16.56. Found: C, 71.35; H, 6.88; N, 16.56.

EXAMPLE 28

6-Chloro-3-[4-(4-methoxyphenyl)piperazin-1-ylmethyl]-1H-indazole

10 The title compound was prepared as a white crystalline solid following the general procedure described in EXAMPLE 24; mp 182 – 184 °C (from EtOAc); ¹H NMR (360 MHz, d₆-DMSO) δ 12.96 (bs, 1 H, NH), 7.90 (d, $J = 8.7$ Hz, 1 H, indazole), 7.56 (d, $J = 1.5$ Hz, 1 H, indazole), 7.11 (dd, $J = 8.7,$
15 1.5 Hz, 1 H, indazole), 6.85 (d, $J = 9.2$ Hz, 2 H, Ph), 6.79 (d, $J = 9.2$ Hz, 2 H, Ph), 3.87 (s, 2 H, Ar-CH₂N), 3.67 (s, 3 H, OMe), 2.99 (m, 4 H, piperazine), 2.56 (m, 4 H, piperazine); MS (CI+) m/e 357 (M+H⁺); Anal. calcd for C₁₉H₂₁N₄OCl: C, 63.95; H, 5.93; N, 15.70. Found: C, 64.24; H, 5.86; N, 15.54.

20

EXAMPLE 29

7-Iodo-3-[4-(4-methoxyphenyl)piperazin-1-ylmethyl]-1H-indazole

The title compound was prepared as a white crystalline solid following the general procedure described in EXAMPLE
25 24; dihydrogen oxalate salt: mp 185 – 186 °C (from EtOAc); ¹H

- 43 -

NMR (360 MHz, d₆-DMSO) δ 13.01 (bs, 1 H, NH), 7.98 (d, J = 7.9 Hz, 1 H, indazole), 7.81 (d, J = 7.2 Hz, 1 H, indazole), 6.98 (t, J = 7.2 Hz, 1 H, indazole), 6.89 (d, J = 9.2 Hz, 2 H, Ph), 6.82 (d, J = 9.2 Hz, 2 H, Ph), 4.33 (s, 2 H, Ar-CH₂N), 3.68 (s, 3 H, OMe),
5 3.13 (bs, 4 H, piperazine), 3.00 (bs, 4 H, piperazine); MS (CI+) m/e 449 (M+H⁺); Anal. calcd for C₁₉H₂₁N₄IO.2C₂H₂O₄: C, 43.96; H, 4.01; N, 8.92. Found: C, 43.76; H, 3.86; N, 8.60.

EXAMPLE 30

7-Fluoro-3-[4-(4-methoxyphenyl)piperazin-1-ylmethyl]-
10 1H-indazole

The title compound was prepared as a white crystalline solid following the general procedure described in EXAMPLE 24; mp 178 – 179 °C (from EtOAc); ¹H NMR (360 MHz, d₆-DMSO) δ 13.40 (bs, 1 H, NH), 7.71 (d, J = 8.0 Hz, 1 H,
15 indazole), 7.17 (dd, J = 11.4, 7.6 Hz, 1 H, indazole), 7.07 (dt, J = 7.8, 4.5 Hz, 1 H, indazole), 6.86 (d, J = 9.2 Hz, 2 H, Ph), 6.79 (d, J = 9.2 Hz, 2 H, Ph), 3.90 (s, 2 H, Ar-CH₂N), 3.67 (s, 3 H, OMe), 2.99 (m, 4 H, piperazine), 2.57 (m, 4 H, piperazine); MS (CI+) m/e 341 (M+H⁺); Anal. calcd for C₁₉H₂₁FN₄O: C, 67.04; H, 6.22;
20 N, 16.46. Found: C, 67.07; H, 6.17; N, 16.14.

EXAMPLE 31

7-Fluoro-3-[4-(4-methylphenyl)piperazin-1-ylmethyl]-
1H-indazole

The title compound was prepared as a white crystalline
25 solid following the general procedure described in EXAMPLE

24; mp 176 – 177 °C (from EtOAc); ¹H NMR (360 MHz, d₆-DMSO) δ 13.38 (bs, 1 H, NH), 7.72 (d, *J* = 8.0 Hz, 1 H, indazole), 7.16 (m, 1 H, indazole), 7.06 (m, 1 H, indazole), 6.99 (d, *J* = 8.6 Hz, 2 H, Ph), 6.80 (d, *J* = 8.6 Hz, 2 H, Ph), 3.90 (s, 2 H, Ar-CH₂N), 3.05 (m, 4 H, piperazine), 2.57 (m, 4 H, piperazine), 2.18 (s, 3 H, Me); MS (CI+) *m/e* 325 (M+H⁺); Anal. calcd for C₁₉H₂₁N₄F: C, 70.35; H, 6.53; N, 17.27. Found: C, 70.19; H, 6.59; N, 16.87.

EXAMPLE 32

10 6,7-Difluoro-3-[4-(4-methoxyphenyl)piperazin-1-ylmethyl]-1H-indazole

The title compound was prepared as a white crystalline solid following the general procedure described in EXAMPLE 24; mp 195 – 197 °C (from EtOAc); ¹H NMR (360 MHz, d₆-DMSO) δ 13.55 (bs, 1 H, NH), 7.72 (dd, *J* = 8.9, 4.4 Hz, 1 H, indazole), 7.15 (m, 1 H, indazole), 6.86 (d, *J* = 6.7 Hz, 2 H, Ph), 6.79 (d, *J* = 6.7 Hz, 2 H, Ph), 3.89 (s, 2 H, Ar-CH₂N), 3.67 (s, 3 H, OMe), 2.99 (m, 4 H, piperazine), 2.57 (m, 4 H, piperazine); MS (CI+) *m/e* 359 (M+H⁺); Anal. calcd for C₁₉H₂₀F₂N₄O: C, 63.68; H, 5.63; N, 15.63. Found: C, 63.52; H, 5.50; N, 15.44.

EXAMPLE 33

6,7-Difluoro-3-[4-(4-chlorophenyl)piperazin-1-ylmethyl]-1H-indazole

25 The title compound was prepared as a white crystalline solid following the general procedure described in EXAMPLE

- 45 -

24; mp 167 – 168 °C (from EtOAc); ¹H NMR (360 MHz, d₆-DMSO) δ 13.55 (bs, 1 H, NH), 7.72 (dd, *J* = 8.9, 4.4 Hz, 1 H, indazole), 7.20 (d, *J* = 9.0 Hz, 2 H, Ph), 7.15 (m, 1 H, indazole), 6.91 (d, *J* = 9.0 Hz, 2 H, Ph), 3.89 (s, 2 H, Ar-CH₂N), 3.11 (m, 4 H, piperazine), 2.56 (m, 4 H, piperazine); MS (CI+) *m/e* 363 (M+H⁺); Anal. calcd for C₁₈H₁₇N₄F₂Cl: C, 59.59; H, 4.72; N, 15.44. Found: C, 59.54; H, 4.77; N, 15.15.

EXAMPLE 34

10 7-Chloro-3-[4-(4-methoxyphenyl)piperazin-1-ylmethyl]-1H-indazole

 The title compound was prepared as a white crystalline solid following the general procedure described in EXAMPLE 24; mp 190 – 191 °C (from EtOAc / MeOH); ¹H NMR (360 MHz, d₆-DMSO) δ 13.36 (bs, 1 H, NH), 7.87 (d, *J* = 7.8 Hz, 1 H, indazole), 7.43 (d, *J* = 6.8 Hz, 1 H, indazole), 7.11 (t, *J* = 7.8 Hz, 1 H, indazole), 6.86 (d, *J* = 6.7 Hz, 2 H, Ph), 6.79 (d, *J* = 6.7 Hz, 2 H, Ph), 3.90 (s, 2 H, Ar-CH₂N), 3.67 (s, 3 H, OMe), 2.99 (m, 4 H, piperazine), 2.57 (m, 4 H, piperazine); MS (CI+) *m/e* 357 (M+H⁺); Anal. calcd for C₁₉H₂₁N₄ClO: C, 63.95; H, 5.93; N, 15.70. Found: C, 63.89; H, 5.88; N, 15.34.

EXAMPLE 35

7-Chloro-3-[4-(4-chlorophenyl)piperazin-1-ylmethyl]-1H-indazole

25 The title compound was prepared as a white crystalline solid following the general procedure described in EXAMPLE

- 46 -

24; mp 152 – 154 °C (from EtOAc); ¹H NMR (360 MHz, d₆-DMSO) δ 13.36 (bs, 1 H, NH), 7.87 (d, *J* = 8.0 Hz, 1 H, indazole), 7.43 (d, *J* = 7.4 Hz, 1 H, indazole), 7.20 (d, *J* = 9.0 Hz, 2 H, Ph), 7.11 (t, *J* = 8.0 Hz, 1 H, indazole), 6.91 (d, *J* = 9.0 Hz, 2 H, Ph), 3.90 (s, 2 H, Ar-CH₂N), 3.11 (m, 4 H, piperazine), 2.57 (m, 4 H, piperazine); MS (CI+) *m/e* 361 (M+H⁺); Anal. calcd for C₁₈H₁₈N₄Cl₂: C, 59.84; H, 5.02; N, 15.51. Found: C, 59.77; H, 4.76; N, 15.33.

EXAMPLE 36

10 3-[4-Benzo[1.3]dioxol-5-yl]piperazin-1-ylmethyl-7-chloro-1H-indazole

The title compound was prepared as a white crystalline solid following the general procedure described in EXAMPLE 24; mp 173 – 174 °C (from EtOAc); ¹H NMR (360 MHz, d₆-DMSO) δ 13.33 (bs, 1 H, NH), 7.86 (d, *J* = 8.0 Hz, 1 H, indazole), 7.42 (d, *J* = 7.4 Hz, 1 H, indazole), 7.10 (t, *J* = 8.0 Hz, 1 H, indazole), 6.72 (d, *J* = 8.4 Hz, 1 H, Ph), 6.63 (s, 1 H, Ph), 6.30 (d, *J* = 8.4 Hz, 1 H, Ph), 5.89 (s, 2 H, O-CH₂-O), 3.89 (s; 2 H, Ar-CH₂N), 2.98 (m, 4 H, piperazine), 2.55 (m, 4 H, piperazine); MS (CI+) *m/e* 371 (M+H⁺); Anal. calcd for C₁₉H₁₉N₄ClO₂·¼ H₂O: C, 60.80; H, 5.24; N, 14.93. Found: C, 60.89; H, 5.08; N, 14.68.

- 47 -

EXAMPLE 377-Chloro-3-[4-(3-trifluoromethylphenyl)piperazin-1-ylmethyl]-1H-indazole

5 The title compound was prepared as a white crystalline solid following the general procedure described in EXAMPLE 24. Hydrogen oxalate salt: mp 133 – 134 °C (from EtOAc); ¹H NMR (360 MHz, d₆-DMSO) δ 7.91 (d, *J* = 8.2 Hz, 1 H, indazole), 7.47 (d, *J* = 7.4 Hz, 1 H, indazole), 7.42 (t, *J* = 8.0 Hz, 1 H, indazole), 7.22 – 7.14 (m, 3 H, aromatic), 7.08 (d, *J* = 7.6 Hz, 1 H, Ph), 4.19, Ar-CH₂N), 3.31 (bs, 4 H, piperazine), 2.85 (bs, 4 H, piperazine); MS (CI+) *m/e* 395 (M+H⁺); Anal. calcd for C₁₉H₁₈N₄ClF₃·C₂O₄H₂·¼ H₂O: C, 51.54; H, 4.22; N, 11.45. Found: C, 51.75; H, 4.05; N, 11.15.

10

EXAMPLE 38

15 7-Chloro-3-[4-(4-methylphenyl)piperazin-1-ylmethyl]-1H-indazole

The title compound was prepared as a white crystalline solid following the general procedure described in EXAMPLE 24; mp 187 – 188 °C (from EtOAc); ¹H NMR (360 MHz, d₆-DMSO) δ 13.35 (bs, 1 H, NH), 7.87 (d, *J* = 8.2 Hz, 1 H, indazole), 7.42 (d, *J* = 8.0 Hz, 1 H, indazole), 7.11 (t, *J* = 8.2 Hz, 1 H, indazole), 6.99 (d, *J* = 8.3 Hz, 2 H, Ph), 6.80 (d, *J* = 8.3 Hz, 2 H, Ph), 3.90 (s, 2 H, Ar-CH₂N), 3.05 (m, 4 H, piperazine), 2.57 (m, 4 H, piperazine), 2.18 (s, 3 H, Me); MS (CI+) *m/e* 341

20

(M+H⁺); Anal. calcd for C₁₉H₂₁N₄Cl: C, 66.95; H, 6.21; N, 16.44.
Found: C, 67.11; H, 6.21; N, 16.34.

EXAMPLE 39

5 7-Chloro-3-[4-(5-chloropyridin-2-yl)piperazin-1-ylmethyl]-1H-indazole

The title compound was prepared as a white crystalline solid following the general procedure described in EXAMPLE 24; mp 150 – 152 °C (from EtOAc); ¹H NMR (360 MHz, d₆-DMSO) δ 13.37 (bs, 1 H, NH), 8.09 (d, *J* = 2.6 Hz, 1 H, pyridine), 7.88 (d, *J* = 8.0 Hz, 1 H, indazole), 7.57 (dd, *J* = 9.2, 2.6 Hz, 1 H, pyridine), 7.44 (d, *J* = 7.4 Hz, 1 H, indazole), 7.11 (t, *J* = 7.8 Hz, 1 H, indazole), 6.83 (d, *J* = 9.2 Hz, 1 H, pyridine), 3.90 (s, 2 H, Ar-CH₂N), 3.46 (m, 4 H, piperazine), 2.51 (m, 4 H, piperazine); MS (CI⁺) *m/e* 362 (M+H⁺); Anal. calcd for C₁₇H₁₇N₅Cl₂: C, 56.36; H, 4.73; N, 19.33. Found: C, 56.70; H, 4.67; N, 19.07.

EXAMPLE 40

20 3-[4-(7-Chloro-1H-Indazol-3-ylmethyl)piperazin-1-yl]isoquinoline

The title compound was prepared as a bright yellow crystalline solid following the general procedure described in EXAMPLE 24; mp 208 – 209 °C (from EtOAc); ¹H NMR (360 MHz, d₆-DMSO) δ 13.37 (bs, 1 H, NH), 7.91 (d, *J* = 8.1 Hz, 1 H, indazole), 7.86 (d, *J* = 8.2 Hz, 1 H, isoquinoline), 7.65 (d, *J* = 8.3 Hz, 1 H, isoquinoline), 7.53 (dt, *J* = 6.7, 0.9 Hz, 1 H,


- 49 -

isoquinoline), 7.44 (d, $J = 7.3$ Hz, 1 H, indazole), 7.27 (t, $J = 7.9$ Hz, 1 H, isoquinoline), 7.12 (t, $J = 7.7$ Hz, 1 H, indazole), 6.94 (s, 1 H, isoquinoline), 3.93 (s, 2 H, Ar-CH₂N), 3.53 (m, 4 H, piperazine), 2.60 (m, 4 H, piperazine); MS (CI+) m/e 378 (M+H⁺); Anal. calcd for C₂₁H₂₀N₅Cl: C, 66.75; H, 5.34; N, 18.53. Found: C, 66.71; H, 5.01; N, 18.40.

- 50 -

CLAIMS:

1. The use of a compound of formula I, or a
 pharmaceutically acceptable salt thereof or a prodrug
 5 thereof:



(I)

wherein

R represents hydrogen or C₁₋₆ alkyl;

R¹ represents hydrogen, or an optionally
 substituted C₁₋₆ alkyl, C₁₋₆ alkoxy, C₂₋₆ alkenyl, C₂₋₆
 20 alkynyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkyl(C₁₋₆)alkyl,
 aryl, aryl(C₁₋₆)alkyl, aryl(C₁₋₆)alkoxy,
 aryl(C₂₋₆)alkenyl, aryl(C₂₋₆)alkynyl, heteroaryl,
 heteroaryl(C₁₋₆)alkyl, heteroaryl(C₂₋₆)alkenyl or
 heteroaryl(C₂₋₆)alkynyl group;

25 R² represents an optionally substituted C₁₋₆
 alkyl, C₁₋₆ alkoxy, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇
 cycloalkyl, C₃₋₇ cycloalkyl(C₁₋₆)alkyl, aryl,
 aryl(C₁₋₆)alkyl, aryl(C₁₋₆)alkoxy, aryl(C₂₋₆)alkenyl,
 aryl(C₂₋₆)alkynyl, heteroaryl, heteroaryl(C₁₋₆)alkyl,
 30 heteroaryl(C₂₋₆)alkenyl or heteroaryl(C₂₋₆)alkynyl group;


R³, R⁴ and R⁵ independently represent hydrogen,
 hydrocarbon, a heterocyclic group, halogen, cyano,
 trifluoromethyl, nitro, -OR^a, -SR^a, -SOR^a, -SO₂R^a,
 -SO₂NR^aR^b, -NR^aR^b, -NR^aCOR^b, -NR^aCO₂R^b, -COR^a, -CO₂R^a or
 35 -CONR^aR^b; and

- 51 -

R^a and R^b independently represent hydrogen, hydrocarbon or a heterocyclic group; for the manufacture of a medicament for the treatment and/or prevention of psychotic disorders.

5

2. The use as claimed in claim 1 of a compound represented by formula IIA, and pharmaceutically acceptable salts thereof and prodrugs thereof:



(IIA)

wherein

20

n is zero, 1, 2 or 3;

R^{11} represents hydrogen or C_{1-6} alkyl;

R^{13} and R^{14} independently represent hydrogen, halogen, cyano, nitro, trifluoromethyl, amino, C_{1-6} alkylamino, di(C_{1-6})alkylamino, C_{1-6} alkyl, C_{1-6} alkoxy, aryl(C_{1-6})alkoxy or C_{2-6} alkylcarbonyl; or R^{13} and R^{14} , when situated on adjacent carbon atoms, together represent methylenedioxy; and

25

30

R^{17} and R^{18} independently represent hydrogen, halogen, cyano, nitro, trifluoromethyl, amino, C_{1-6} alkylamino, di(C_{1-6})alkylamino, C_{1-6} alkyl, C_{1-6} alkoxy, aryl(C_{1-6})alkoxy or C_{2-6} alkylcarbonyl; or R^{17} and R^{18} , when situated on adjacent carbon atoms, together represent methylenedioxy.

- 52 -


3. The use as claimed in claim 2 wherein, in the compounds of formula IIA, R^{14} and R^{18} both represent hydrogen.

5 4. A method for the treatment and/or prevention of psychotic disorders, which comprises administering to a patient in need of such treatment an effective amount of a compound of formula I as defined in claim 1, or a pharmaceutically acceptable salt thereof.

10 5. The method as claimed in claim 4 wherein the compound administered is represented by formula IIA as defined in claim 2, or a pharmaceutically acceptable salt thereof or a prodrug thereof.

15 6. The method as claimed in claim 5 wherein, in the compounds of formula IIA, R^{14} and R^{18} both represent hydrogen.

20 7. A compound of formula IIB, or a salt or prodrug thereof:



(IIB)

wherein


n , R^{11} , R^{13} and R^{14} are as defined in claim 2;

and


Y represents a group of formula Y_a , Y_b , Y_c or

35 Y_d :


- 53 -




(Y a)



(Y b)



(Y c)



(Y d)

in which

R^{27} represents halogen, trifluoromethyl, C_{1-6} alkyl or C_{1-6} alkoxy; and

20 R^{28} represents hydrogen, halogen, trifluoromethyl, C_{1-6} alkyl or C_{1-6} alkoxy.

8. A compound as claimed in claim 7 wherein
 25 R^{14} represents hydrogen; Y represents a group of formula Y a, Y b or Y c; R^{27} represents halogen, C_{1-6} alkyl or C_{1-6} alkoxy; and R^{28} represents hydrogen, halogen, C_{1-6} alkyl or C_{1-6} alkoxy.

9. A compound selected from:

30 3-[4-(4-chlorophenyl)piperazin-1-ylmethyl]-1H-indazole;
 3-(4-phenylpiperazin-1-ylmethyl)-1H-indazole;
 3-(4-benzylpiperazin-1-ylmethyl)-1H-indazole;
 3-(3-methyl-4-phenylpiperazin-1-ylmethyl)-1H-indazole;
 3-[4-(4-fluorophenyl)piperazin-1-ylmethyl]-1H-indazole;
 35 3-[4-(2-methylphenyl)piperazin-1-ylmethyl]-1H-indazole;
 3-[4-(3-methylphenyl)piperazin-1-ylmethyl]-1H-indazole;

- 3-[4-(4-methylphenyl)piperazin-1-ylmethyl]-1H-indazole;
3-[4-(pyrimidin-2-yl)piperazin-1-ylmethyl]-1H-indazole;
3-[4-(3,4-methylenedioxybenzyl)piperazin-1-ylmethyl]-1H-indazole;
5 3-[4-(3-trifluoromethylphenyl)piperazin-1-ylmethyl]-1H-indazole;
3-[4-(pyrid-2-yl)piperazin-1-ylmethyl]-1H-indazole;
3-[4-(4-methoxyphenyl)piperazin-1-ylmethyl]-1H-indazole;
3-[4-(4-acetylphenyl)piperazin-1-ylmethyl]-1H-indazole;
10 6-fluoro-3-[4-(4-methoxyphenyl)piperazin-1-ylmethyl]-1H-indazole;
3-[4-(4-chlorophenyl)piperazin-1-ylmethyl]-6-fluoro-1H-indazole;
6-fluoro-3-[4-(2-phenylethyl)piperazin-1-ylmethyl]-1H-indazole;
15 6-chloro-3-[4-(4-methoxyphenyl)piperazin-1-ylmethyl]-1H-indazole;
7-chloro-3-[4-(4-methoxyphenyl)piperazin-1-ylmethyl]-1H-indazole;
20 3-[4-(2-phenylethyl)piperazin-1-ylmethyl]-1H-indazole;
3-[4-(5-chloropyrid-2-yl)piperazin-1-ylmethyl]-1H-indazole;
3-[4-(5-methylpyrid-2-yl)piperazin-1-ylmethyl]-1H-indazole;
25 3-[4-(5-methoxypyrid-2-yl)piperazin-1-ylmethyl]-1H-indazole;
3-[4-(quinolin-2-yl)piperazin-1-ylmethyl]-1H-indazole;
3-[4-(isoquinolin-3-yl)piperazin-1-ylmethyl]-1H-indazole;
3-[4-(3,4-methylenedioxyphenyl)piperazin-1-ylmethyl]-1H-indazole;
30 3-[4-(3,5-bis(trifluoromethyl)phenyl)piperazin-1-ylmethyl]-1H-indazole;
3-[4-(5-trifluoromethylpyrid-2-yl)piperazin-1-ylmethyl]-1H-indazole;
35 3-[4-(4-trifluoromethylpyrid-2-yl)piperazin-1-ylmethyl]-1H-indazole;

- 55 -

- 3-(4-benzylcarbonylpiperazin-1-ylmethyl)-6-fluoro-1H-indazole;
7-iodo-3-[4-(4-methoxyphenyl)piperazin-1-ylmethyl]-1H-indazole;
5 7-fluoro-3-[4-(4-methoxyphenyl)piperazin-1-ylmethyl]-1H-indazole;
7-fluoro-3-[4-(4-methylphenyl)piperazin-1-ylmethyl]-1H-indazole;
6,7-difluoro-3-[4-(4-methoxyphenyl)piperazin-1-ylmethyl]-1H-indazole;
10 3-[4-(4-chlorophenyl)piperazin-1-ylmethyl]-6,7-difluoro-1H-indazole;
7-chloro-3-[4-(4-chlorophenyl)piperazin-1-ylmethyl]-1H-indazole;
15 7-chloro-3-[4-(3,4-methylenedioxyphenyl)piperazin-1-ylmethyl]-1H-indazole;
7-chloro-3-[4-(3-trifluoromethylphenyl)piperazin-1-ylmethyl]-1H-indazole;
7-chloro-3-[4-(4-methylphenyl)piperazin-1-ylmethyl]-1H-indazole;
20 7-chloro-3-[4-(5-chloropyrid-2-yl)piperazin-1-ylmethyl]-1H-indazole;
7-chloro-3-[4-(isoquiolin-3-yl)piperazin-1-ylmethyl]-1H-indazole;
25 and salts and prodrugs thereof.

10. A pharmaceutical composition comprising a compound as claimed in any one of claims 7 to 9 in association with a pharmaceutically acceptable carrier.

30

11. A compound as claimed in any one of claims 7 to 9 for use in therapy.

12. The use of a compound as claimed in any one of claims 7 to 9 for the manufacture of a medicament

35

- 56 -

for the treatment and/or prevention of psychotic disorders.

- 5 13. A method for the treatment and/or prevention of psychotic disorders, which comprises administering to a patient in need of such treatment an effective amount of a compound as claimed in any one of claims 7 to 9.

INTERNATIONAL SEARCH REPORT

Intern. Appl. No.
PCT/GB 94/00504

A. CLASSIFICATION OF SUBJECT MATTER
IPC 5 C07D403/06 A61K31/495 //(C07D403/06,231:00,295:00)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 5 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP,A,0 378 255 (JANSSEN PHARMACEUTICA N.V.) 18 July 1990 see page 14, lines 11-22 Table 3, Table 6 see page 25 - page 27 ---	1-3,7-12
Y	EP,A,0 281 309 (PFIZER INC.) 7 September 1988 see page 3, lines 55-58 see claim 1 ---	1-3,7-12
Y	EP,A,0 417 653 (HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED) 20 March 1991 see claim 1 --- -/--	1-3,7-12

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

20 June 1994

Date of mailing of the international search report

- 4. 07. 94

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Lauro, P

INTERNATIONAL SEARCH REPORT

Intern. Application No

PCT/GB 94/00504

C(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	CHEMICAL ABSTRACTS, vol. 57, no. 10, 12 November 1962, Columbus, Ohio, US; abstract no. 12467h, N.V. DUDYKINA, N.K. KOCHETKOV 'Some derivatives of 3-aminomethylindazole' & ZH. OBSHCH. KHIM. vol. 32 , 1962 pages 81 - 84 ----	1-3,7-12
A	WO,A,92 17475 (PFIZER INC.) 15 October 1992 cited in the application see page 1, lines 7-31 see page 92; example 36 ----	7-12
A	US,A,3 362 956 (SYDNEY ARCHER) 9 January 1968 cited in the application ----	7-12
A	US,A,3 678 059 (H. W. GSCHWEND, G. DE STEVENS) 18 July 1972 cited in the application ----	7-12
A	EP,A,0 376 607 (H. LUNDBECK A/S) 4 July 1990 see page 1, lines 4-10 and claim 1 -----	1-3,7-12

INTERNATIONAL SEARCH REPORT

Information on patent family members

Intern. Application No

PCT/GB 94/00504

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-0378255	18-07-90	AU-B- 617918	05-12-91
		AU-A- 4777990	12-07-90
		DE-D- 69008366	01-06-94
		JP-A- 2225482	07-09-90
		US-A- 5284854	08-02-94
		US-A- 5140029	18-08-92
		US-A- 5256659	26-10-93
EP-A-0281309	07-09-88	AU-B- 583762	04-05-89
		AU-A- 1253788	01-09-88
		CA-A- 1300139	05-05-92
		FI-B- 91868	13-05-94
EP-A-0417653	20-03-91	US-A- 4954503	04-09-90
		AU-A- 6229890	14-03-91
		CA-A- 2024996	12-03-91
		JP-A- 3167175	19-07-91
		US-A- 5077405	31-12-91
WO-A-9217475	15-10-92	AU-A- 1878292	02-11-92
		CA-A- 2107105	29-09-92
		CN-A- 1065267	14-10-92
		JP-T- 6500794	27-01-94
US-A-3362956		US-A- 3472854	14-10-69
US-A-3678059	18-07-72	NONE	
EP-A-0376607	04-07-90	AU-B- 637991	17-06-93
		AU-A- 4719889	05-07-90
		DE-D- 68913487	07-04-94
		JP-A- 2225460	07-09-90
		US-A- 5002948	26-03-91